Tissue-specific	O
activity	O
of	O
the	O
gammac	B-DNA
chain	I-DNA
gene	I-DNA
promoter	I-DNA
depends	O
upon	O
an	O
Ets	B-DNA
binding	I-DNA
site	I-DNA
and	O
is	O
regulated	O
by	O
GA-binding	B-protein
protein	I-protein
.	O

The	O
gammac	B-protein
chain	I-protein
is	O
a	O
subunit	O
of	O
multiple	O
cytokine	B-protein
receptors	I-protein
(	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-9	B-protein
,	O
and	O
IL-15	B-protein
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
restricted	O
to	O
hematopoietic	B-cell_type
lineages	I-cell_type
.	O

A	O
defect	O
in	O
gammac	O
leads	O
to	O
the	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
characterized	O
by	O
a	O
block	O
in	O
T	O
cell	O
differentiation	O
.	O

In	O
order	O
to	O
better	O
characterize	O
the	O
human	B-DNA
gammac	I-DNA
promoter	I-DNA
and	O
define	O
the	O
minimal	B-DNA
tissue-specific	I-DNA
promoter	I-DNA
region	I-DNA
,	O
progressive	O
5'-deletion	B-DNA
constructs	I-DNA
of	O
a	O
segment	O
extending	O
1053	B-DNA
base	I-DNA
pairs	I-DNA
upstream	I-DNA
of	O
the	O
major	B-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
were	O
generated	O
and	O
tested	O
for	O
promoter	O
activity	O
in	O
various	O
hematopoietic	B-cell_type
and	I-cell_type
nonhematopoietic	I-cell_type
cell	I-cell_type
types	I-cell_type
.	O

The	O
-1053/+34	B-DNA
construct	I-DNA
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	B-cell_type
origin	I-cell_type
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested	O
.	O

The	O
region	O
downstream	O
of	O
-90	O
appeared	O
critical	O
for	O
basal	O
promoter	O
activity	O
.	O

It	O
contains	O
two	O
potential	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
conserved	O
in	O
the	O
murine	B-DNA
gammac	I-DNA
promoter	I-DNA
gene	I-DNA
,	O
one	O
of	O
which	O
was	O
found	O
essential	O
for	O
functional	O
promoter	O
activity	O
as	O
determined	O
by	O
mutational	O
analysis	O
.	O

The	O
functional	O
Ets	B-DNA
binding	I-DNA
site	I-DNA
was	O
found	O
to	O
bind	O
Ets	B-protein
family	I-protein
proteins	I-protein
,	O
principally	O
GA-binding	B-protein
protein	I-protein
and	O
Elf-1	B-protein
and	O
could	O
be	O
transactivated	O
by	O
GABPalpha	B-protein
and	O
-beta	B-protein
synergistically	O
.	O

These	O
results	O
indicate	O
that	O
,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	B-DNA
promoter	I-DNA
,	O
GA-binding	B-protein
protein	I-protein
is	O
an	O
essential	O
component	O
of	O
gammac	O
basal	O
promoter	O
activity	O
.	O

Although	O
GABP	B-protein
expression	O
is	O
not	O
restricted	O
to	O
the	O
hematopoietic	B-cell_type
lineage	I-cell_type
,	O
its	O
interaction	O
with	O
other	O
specific	B-protein
factors	I-protein
may	O
contribute	O
to	O
the	O
tissue-specific	O
expression	O
of	O
the	O
gammac	B-DNA
gene	I-DNA
.	O

THs	NULL
JourNaL	NULL
or	NULL
BroLocicaL	NULL
CHEMISTRY	NULL
©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

271	NULL
,	NULL
No	NULL
.	NULL

25	NULL
,	NULL
Issue	NULL
of	NULL
June	NULL
21	NULL
,	NULL
pp	NULL
.	NULL

14849-14855	NULL
,	NULL
1996	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Tissue-specific	NULL
Activity	NULL
of	NULL
the	NULL
yc	NULL
Chain	NULL
Gene	NULL
Promoter	NULL
Depends	NULL
upon	NULL
an	NULL
Ets	NULL
Binding	NULL
Site	NULL
and	NULL
Is	NULL
Regulated	NULL
by	NULL
GA-binding	NULL
Protein*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
November	NULL
16	NULL
,	NULL
1995	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
February	NULL
14	NULL
,	NULL
1996	NULL
)	NULL
Sophie	NULL
Markiewicz	NULL
}	NULL
§	NULL
,	NULL
Rémy	NULL
Bosselut1	NULL
,	NULL
Francoise	NULL
Le	NULL
Deist	NULL
}	NULL
,	NULL
Jean-Pierre	NULL
de	NULL
Villartay	NULL
$	NULL
,	NULL
Claire	NULL
Hivrozt	NULL
,	NULL
Jacques	NULL
Ghysdaelf	NULL
,	NULL
Alain	NULL
Fischer	NULL
$	NULL
,	NULL
and	NULL
Genevieve	NULL
de	NULL
Saint	NULL
Basile	NULL
?	NULL

#	NULL
]	NULL
From	NULL
{	NULL
INSERM	NULL
U429	NULL
,	NULL
Hopital	NULL
Necker-Enfants	NULL
Malades	NULL
,	NULL
149	NULL
rue	NULL
de	NULL
Sevres	NULL
,	NULL
75743	NULL
Paris	NULL
Cedex	NULL
15	NULL
and	NULL
(	NULL
CNRS	NULL
UMR	NULL
146	NULL
,	NULL
Institut	NULL
Curie	NULL
,	NULL
Section	NULL
de	NULL
Recherche	NULL
,	NULL
Centre	NULL
Universitaire	NULL
,	NULL
Batiment	NULL
110	NULL
,	NULL
91405	NULL
Orsay	NULL
Cedex	NULL
,	NULL
France	NULL
The	NULL
y¢	NULL
chain	NULL
is	NULL
a	NULL
subunit	NULL
of	NULL
multiple	NULL
cytokine	NULL
receptors	NULL
(	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-2	NULL
,	NULL
IL-4	NULL
,	NULL
IL-7	NULL
,	NULL
IL-9	NULL
,	NULL
and	NULL
IL-15	NULL
)	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
which	NULL
is	NULL
restricted	NULL
to	NULL
hematopoietic	NULL
lin-eages	NULL
.	NULL

A	NULL
defect	NULL
in	NULL
yc	NULL
leads	NULL
to	NULL
the	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
characterized	NULL
by	NULL
a	NULL
block	NULL
in	NULL
T	NULL
cell	NULL
differentiation	NULL
.	NULL

In	NULL
order	NULL
to	NULL
better	NULL
characterize	NULL
the	NULL
human	NULL
ye	NULL
promoter	NULL
and	NULL
define	NULL
the	NULL
minimal	NULL
tissue-specific	NULL
promoter	NULL
region	NULL
,	NULL
progressive	NULL
5'-deletion	NULL
constructs	NULL
of	NULL
a	NULL
segment	NULL
extending	NULL
1053	NULL
base	NULL
pairs	NULL
upstream	NULL
of	NULL
the	NULL
major	NULL
transcription	NULL
start	NULL
site	NULL
were	NULL
generated	NULL
and	NULL
tested	NULL
for	NULL
promoter	NULL
activity	NULL
in	NULL
various	NULL
hematopoietic	NULL
and	NULL
nonhematopoietic	NULL
cell	NULL
types	NULL
.	NULL

The	NULL
-1053/+34	NULL
construct	NULL
allowed	NULL
promoter	NULL
activity	NULL
only	NULL
in	NULL
cells	NULL
of	NULL
hematopoietic	NULL
origin	NULL
,	NULL
and	NULL
tissue	NULL
specificity	NULL
was	NULL
conserved	NULL
in	NULL
all	NULL
other	NULL
constructs	NULL
tested	NULL
.	NULL

The	NULL
region	NULL
downstream	NULL
of	NULL
-90	NULL
appeared	NULL
critical	NULL
for	NULL
basal	NULL
promoter	NULL
activity	NULL
.	NULL

It	NULL
contains	NULL
two	NULL
potential	NULL
Ets	NULL
binding	NULL
sites	NULL
conserved	NULL
in	NULL
the	NULL
murine	NULL
ye	NULL
promoter	NULL
gene	NULL
,	NULL
one	NULL
of	NULL
which	NULL
was	NULL
found	NULL
essential	NULL
for	NULL
functional	NULL
promoter	NULL
activity	NULL
as	NULL
determined	NULL
by	NULL
mutational	NULL
analysis	NULL
.	NULL

The	NULL
functional	NULL
Ets	NULL
binding	NULL
site	NULL
was	NULL
found	NULL
to	NULL
bind	NULL
Ets	NULL
family	NULL
proteins	NULL
,	NULL
principally	NULL
GA-binding	NULL
protein	NULL
and	NULL
Elf-1	NULL
and	NULL
could	NULL
be	NULL
transactivated	NULL
by	NULL
GABPa	NULL
and	NULL
-B	NULL
synergistically	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
,	NULL
as	NULL
already	NULL
reported	NULL
for	NULL
the	NULL
IL2RB	NULL
promoter	NULL
,	NULL
GA-binding	NULL
protein	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
yc	NULL
basal	NULL
promoter	NULL
activity	NULL
.	NULL

Although	NULL
GABP	NULL
expression	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
the	NULL
hematopoietic	NULL
lineage	NULL
,	NULL
its	NULL
interaction	NULL
with	NULL
other	NULL
specific	NULL
factors	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
yc	NULL
gene	NULL
.	NULL

The	NULL
common	NULL
y	NULL
(	NULL
yc	NULL
)	NULL
chain	NULL
that	NULL
functions	NULL
as	NULL
a	NULL
subunit	NULL
of	NULL
the	NULL
receptors	NULL
for	NULL
IL-2	NULL
``	NULL
(	NULL
1	NULL
)	NULL
,	NULL
IL-4	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
,	NULL
IL-7	NULL
(	NULL
4-5	NULL
)	NULL
,	NULL
IL-9	NULL
(	NULL
6	NULL
)	NULL
,	NULL
and	NULL
IL-15	NULL
(	NULL
7	NULL
)	NULL
is	NULL
a	NULL
pivotal	NULL
molecule	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

A	NULL
functional	NULL
defect	NULL
of	NULL
yc	NULL
chain	NULL
leads	NULL
to	NULL
the	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
(	NULL
SCID	NULL
X1	NULL
)	NULL
(	NULL
8	NULL
)	NULL
.	NULL

SCID	NULL
X1	NULL
patients	NULL
develop	NULL
severe	NULL
and	NULL
persistent	NULL
infections	NULL
resulting	NULL
in	NULL
failure	NULL
to	NULL
thrive	NULL
and	NULL
early	NULL
death	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
curative	NULL
bone	NULL
marrow	NULL
transplantation	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
TAssociation	NULL
Francaise	NULL
contre	NULL
les	NULL
Myopathies	NULL
(	NULL
AFM	NULL
)	NULL
,	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
(	NULL
ARC	NULL
to	NULL
J.	NULL
G.	NULL
)	NULL
,	NULL
le	NULL
Centre	NULL
National	NULL
de	NULL
la	NULL
Recherche	NULL
Scientifique	NULL
(	NULL
CNRS	NULL
)	NULL
,	NULL
Institut	NULL
Curie	NULL
,	NULL
and	NULL
l'Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
(	NULL
INSERM	NULL
)	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
17834	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

§	NULL
Student	NULL
at	NULL
the	NULL
René	NULL
Descartes-Paris	NULL
V	NULL
University	NULL
and	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Ministére	NULL
de	NULL
la	NULL
Recherche	NULL
et	NULL
de	NULL
Enseignement	NULL
Su-périeur	NULL
(	NULL
MRES	NULL
)	NULL
.	NULL

|	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
33	NULL
1	NULL
44	NULL
49	NULL
50	NULL
80	NULL
;	NULL
Fax	NULL
:	NULL
33	NULL
1	NULL
42	NULL
73	NULL
06	NULL
40	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
SCID	NULL
,	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
;	NULL
NK	NULL
,	NULL
natural	NULL
killer	NULL
;	NULL
EBS	NULL
,	NULL
Ets	NULL
binding	NULL
site	NULL
;	NULL
GABP	NULL
,	NULL
GA-binding	NULL
protein	NULL
;	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
.	NULL

SCID	NULL
X1	NULL
is	NULL
characterized	NULL
by	NULL
defective	NULL
T	NULL
lymphocyte	NULL
and	NULL
natural	NULL
killer	NULL
cell	NULL
(	NULL
NK	NULL
)	NULL
differentiation	NULL
,	NULL
whereas	NULL
B	NULL
cells	NULL
appeared	NULL
principally	NULL
affected	NULL
in	NULL
their	NULL
functions	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

9	NULL
)	NULL
.	NULL

yc	NULL
chain	NULL
is	NULL
thus	NULL
critically	NULL
involved	NULL
in	NULL
the	NULL
proliferation	NULL
and	NULL
functional	NULL
differentiation	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

yc	NULL
chain	NULL
expression	NULL
appears	NULL
restricted	NULL
to	NULL
the	NULL
hematopoietic	NULL
lineages	NULL
(	NULL
1	NULL
)	NULL
.	NULL

It	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
expressed	NULL
at	NULL
the	NULL
surface	NULL
of	NULL
all	NULL
peripheral	NULL
lymphocyte	NULL
popula-tions	NULL
,	NULL
of	NULL
NK	NULL
cells	NULL
,	NULL
of	NULL
monocytes	NULL
,	NULL
and	NULL
of	NULL
granulocytes	NULL
(	NULL
10	NULL
)	NULL
.	NULL

During	NULL
T	NULL
cells	NULL
ontogeny	NULL
,	NULL
the	NULL
yc	NULL
chain	NULL
is	NULL
detected	NULL
at	NULL
all	NULL
stages	NULL
of	NULL
differentiation	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

ye	NULL
chain	NULL
appeared	NULL
constitutively	NULL
expressed	NULL
but	NULL
expression	NULL
can	NULL
be	NULL
modulated	NULL
by	NULL
different	NULL
factors	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
yc	NULL
gene	NULL
promoter	NULL
activity	NULL
was	NULL
found	NULL
to	NULL
be	NULL
enhanced	NULL
by	NULL
12-O-tetradecanoylphorbol-13-acetate	NULL
and	NULL
phytohemagglu-tinin	NULL
A	NULL
stimulation	NULL
while	NULL
decreased	NULL
by	NULL
IL-2	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
T	NULL
cells	NULL
,	NULL
fresh	NULL
human	NULL
monocytes	NULL
were	NULL
reportedly	NULL
enhanced	NULL
for	NULL
IL2Ry	NULL
expression	NULL
by	NULL
either	NULL
IL2	NULL
or	NULL
interferon-y	NULL
stimulation	NULL
,	NULL
but	NULL
this	NULL
enhancement	NULL
results	NULL
from	NULL
ye	NULL
mRNA	NULL
stabilization	NULL
(	NULL
14	NULL
)	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
the	NULL
mechanisms	NULL
and	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
ye	NULL
chain	NULL
expression	NULL
,	NULL
studies	NULL
of	NULL
the	NULL
transcriptional	NULL
regulatory	NULL
region	NULL
were	NULL
initiated	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
show	NULL
that	NULL
the	NULL
5	NULL
'	NULL
regulatory	NULL
region	NULL
of	NULL
yc	NULL
chain	NULL
gene	NULL
contains	NULL
multiple	NULL
potential	NULL
Ets	NULL
binding	NULL
sites	NULL
(	NULL
EBS	NULL
)	NULL
and	NULL
that	NULL
one	NULL
of	NULL
the	NULL
EBS	NULL
present	NULL
in	NULL
the	NULL
region	NULL
,	NULL
recently	NULL
shown	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
basal	NULL
promoter	NULL
activity	NULL
(	NULL
13	NULL
)	NULL
,	NULL
is	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
tissue-specific	NULL
expression	NULL
.	NULL

This	NULL
EBS	NULL
interacts	NULL
in	NULL
vitro	NULL
with	NULL
two	NULL
major	NULL
factors	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
DNA	NULL
binding	NULL
proteins	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
,	NULL
the	NULL
GA-binding	NULL
protein	NULL
(	NULL
GABP	NULL
)	NULL
,	NULL
which	NULL
also	NULL
functions	NULL
as	NULL
transacti-vator	NULL
in	NULL
cotransfection	NULL
assays	NULL
,	NULL
and	NULL
Elf-1	NULL
,	NULL
which	NULL
therefore	NULL
may	NULL
play	NULL
crucial	NULL
roles	NULL
in	NULL
regulating	NULL
ye	NULL
promoter	NULL
activity	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Lines-The	NULL
cell	NULL
lines	NULL
utilized	NULL
in	NULL
this	NULL
study	NULL
were	NULL
the	NULL
human	NULL
Burkitt	NULL
lymphoma	NULL
Raji	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
Jurkat	NULL
cell	NULL
line	NULL
,	NULL
IARC	NULL
301.5	NULL
which	NULL
is	NULL
a	NULL
subclone	NULL
from	NULL
a	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
a	NULL
human	NULL
T	NULL
lymphoma	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
,	NULL
the	NULL
myelogenous	NULL
leukemia	NULL
K562	NULL
cell	NULL
line	NULL
,	NULL
YT	NULL
12	NULL
881-a	NULL
subclone	NULL
from	NULL
the	NULL
human	NULL
NK-like	NULL
cell	NULL
line	NULL
(	NULL
YT-was	NULL
obtained	NULL
from	NULL
D.	NULL
K.	NULL
Smith	NULL
(	NULL
19	NULL
)	NULL
)	NULL
,	NULL
the	NULL
human	NULL
colorectal	NULL
adenocarcinoma	NULL
cell	NULL
line	NULL
DLD-1	NULL
,	NULL
the	NULL
human	NULL
hepatocellular	NULL
carcinoma	NULL
cell	NULL
line	NULL
Hep-G2	NULL
,	NULL
human	NULL
fibroblasts	NULL
,	NULL
and	NULL
an	NULL
Epstein-Barr	NULL
virus-transformed	NULL
B	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
from	NULL
two	NULL
normal	NULL
human	NULL
subjects	NULL
,	NULL
and	NULL
the	NULL
human	NULL
epithelioma	NULL
cell	NULL
line	NULL
Helia	NULL
.	NULL

All	NULL
the	NULL
cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
except	NULL
for	NULL
the	NULL
HeLa	NULL
cell	NULL
line	NULL
which	NULL
was	NULL
cultured	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

DNA	NULL
Sequence	NULL
Analysis-ye	NULL
genomic	NULL
DNA	NULL
was	NULL
isolated	NULL
from	NULL
screening	NULL
of	NULL
an	NULL
X	NULL
chromosome	NULL
enriched	NULL
cosmid	NULL
library	NULL
gridded	NULL
onto	NULL
nylon	NULL
filter	NULL
(	NULL
20	NULL
)	NULL
using	NULL
a	NULL
full-length	NULL
human	NULL
ye	NULL
cDNA	NULL
.	NULL

ye	NULL
genomic	NULL
sequence	NULL
was	NULL
determined	NULL
by	NULL
direct	NULL
cosmid	NULL
sequencing	NULL
using	NULL
*°P-labeled	NULL
oligonucleotides	NULL
and	NULL
the	NULL
CircumVent	NULL
Thermal	NULL
cycle	NULL
dideoxy	NULL
DNA	NULL
sequencing	NULL
kit	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
(	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
synthetic	NULL
primers	NULL
(	NULL
Genset	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Sequences	NULL
of	NULL
primers	NULL
used	NULL
in	NULL
this	NULL
study	NULL
are	NULL
available	NULL
on	NULL
request	NULL
.	NULL

The	NULL
numbering	NULL
of	NULL
all	NULL
oligonucleotides	NULL
and	NULL
sequences	NULL
in	NULL
this	NULL
paper	NULL
is	NULL
based	NULL
on	NULL
assigning	NULL
the	NULL
major	NULL
transcription	NULL
site	NULL
as	NULL
+1	NULL
,	NULL
identified	NULL
by	NULL
primer	NULL
extension	NULL
and	NULL
ribonuclease	NULL
protection	NULL
assays	NULL
(	NULL
21	NULL
)	NULL
.	NULL

14849	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
14850	NULL
Vectors-T'wo	NULL
plasmids	NULL
with	NULL
reporter	NULL
genes	NULL
were	NULL
used	NULL
,	NULL
the	NULL
promoterless	NULL
pGI2	NULL
basic	NULL
vector	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
,	NULL
carrying	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
(	NULL
22	NULL
)	NULL
,	NULL
and	NULL
the	NULL
pRSV-CAT	NULL
plasmid	NULL
(	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
CAT	NULL
plasmid	NULL
)	NULL
,	NULL
which	NULL
carries	NULL
the	NULL
CAT	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
Rous	NULL
sarcoma	NULL
long	NULL
terminal	NULL
repeat	NULL
promoter	NULL
(	NULL
23	NULL
)	NULL
,	NULL
was	NULL
also	NULL
included	NULL
in	NULL
all	NULL
transfection	NULL
experiments	NULL
to	NULL
correct	NULL
for	NULL
variations	NULL
in	NULL
transfection	NULL
effi-ciencies	NULL
.	NULL

The	NULL
GABPa	NULL
,	NULL
GABPB	NULL
cDNAS	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Drs	NULL
.	NULL

Brown	NULL
and	NULL
Mc	NULL
Knight	NULL
)	NULL
,	NULL
and	NULL
the	NULL
Elf-1	NULL
cDNA	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr.	NULL
Leiden	NULL
)	NULL
have	NULL
been	NULL
inserted	NULL
at	NULL
the	NULL
EcoRI	NULL
site	NULL
of	NULL
the	NULL
SV40	NULL
promoter-based	NULL
AEB	NULL
expression	NULL
plasmid	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Plasmid	NULL
Constructs-DNA	NULL
constructs	NULL
including	NULL
varying	NULL
parts	NULL
of	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
yc	NULL
chain	NULL
gene	NULL
were	NULL
generated	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
amplification	NULL
of	NULL
the	NULL
promoter	NULL
sequences	NULL
was	NULL
performed	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
using	NULL
total	NULL
genomic	NULL
DNA	NULL
between	NULL
the	NULL
lower	NULL
26-mer-synthesized	NULL
oligonucleotide	NULL
primer	NULL
for	NULL
the	NULL
common	NULL
3	NULL
``	NULL
end	NULL
at	NULL
+34	NULL
(	NULL
CLP2	NULL
5	NULL
'	NULL
GGG	NULL
GTA	NULL
CCC	NULL
GCT	NULL
TGC	NULL
TCT	NULL
TCA	NULL
TTC	NULL
CC	NULL
3°	NULL
)	NULL
and	NULL
one	NULL
of	NULL
the	NULL
following	NULL
upper	NULL
26-mer	NULL
oligonucleotide	NULL
primers	NULL
in	NULL
order	NULL
to	NULL
generate	NULL
a	NULL
series	NULL
of	NULL
various	NULL
truncated	NULL
5	NULL
'	NULL
ends	NULL
of	NULL
the	NULL
construct	NULL
:	NULL
1053	NULL
CLP1	NULL
,	NULL
5	NULL
GGG	NULL
GTA	NULL
CCA	NULL
GGA	NULL
TGT	NULL
CTT	NULL
GTT	NULL
GGT	NULL
CT	NULL
35	NULL
;	NULL
754	NULL
CLP1	NULL
,	NULL
5	NULL
GGG	NULL
GTA	NULL
CCA	NULL
GAA	NULL
GCA	NULL
GAG	NULL
TGG	NULL
GTT	NULL
AT	NULL
3	NULL
'	NULL
;	NULL
292	NULL
CLP1	NULL
,	NULL
55	NULL
GGG	NULL
GTA	NULL
CCG	NULL
AGG	NULL
AGA	NULL
AGG	NULL
TGG	NULL
TTG	NULL
AG	NULL
3	NULL
'	NULL
;	NULL
166	NULL
CLP1	NULL
55	NULL
GGG	NULL
GTA	NULL
CCA	NULL
CAG	NULL
CAG	NULL
CAC	NULL
CTA	NULL
ATC	NULL
TC	NULL
3	NULL
``	NULL
;	NULL
117	NULL
CLP1	NULL
,	NULL
55	NULL
GGG	NULL
GTA	NULL
CCT	NULL
ATT	NULL
TGC	NULL
CAC	NULL
ACC	NULL
CTC	NULL
TG	NULL
3	NULL
``	NULL
;	NULL
90	NULL
CLP1	NULL
5°	NULL
GGG	NULL
GTA	NULL
CCG	NULL
GTT	NULL
TAT	NULL
AAG	NULL
GTT	NULL
CTT	NULL
TC	NULL
3	NULL
'	NULL
;	NULL
44	NULL
CLP1	NULL
,	NULL
5'GGG	NULL
GTA	NULL
CCT	NULL
GGG	NULL
TGG	NULL
GGA	NULL
GGG	NULL
GTA	NULL
GT	NULL
3	NULL
.	NULL

The	NULL
amplified	NULL
polymerase	NULL
chain	NULL
reaction	NULL
products	NULL
were	NULL
then	NULL
gel-purified	NULL
,	NULL
digested	NULL
with	NULL
the	NULL
KpnI	NULL
enzyme	NULL
,	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
KpnI	NULL
site	NULL
of	NULL
the	NULL
promoterless	NULL
pGI2	NULL
basic	NULL
vector	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
.	NULL

The	NULL
seven	NULL
constructs	NULL
are	NULL
denoted	NULL
in	NULL
the	NULL
study	NULL
as	NULL
-1053/+84	NULL
,	NULL
-754/	NULL
+84	NULL
,	NULL
-292/+834	NULL
,	NULL
-166/+34	NULL
,	NULL
-117/+834	NULL
,	NULL
-90/+84	NULL
,	NULL
and	NULL
-44/+34	NULL
.	NULL

The	NULL
names	NULL
of	NULL
each	NULL
plasmid	NULL
construct	NULL
include	NULL
the	NULL
borders	NULL
of	NULL
the	NULL
inserted	NULL
DNA	NULL
fragments	NULL
in	NULL
base	NULL
pairs	NULL
relative	NULL
to	NULL
the	NULL
major	NULL
transcription	NULL
site	NULL
.	NULL

The	NULL
correct	NULL
sequence	NULL
and	NULL
good	NULL
orientation	NULL
of	NULL
the	NULL
inserts	NULL
were	NULL
verified	NULL
by	NULL
double-stranded	NULL
dideoxy	NULL
sequence	NULL
analysis	NULL
.	NULL

Transfections-Except	NULL
for	NULL
Hela	NULL
cells	NULL
,	NULL
all	NULL
DNA	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
by	NULL
electroporation	NULL
(	NULL
25	NULL
)	NULL
using	NULL
the	NULL
Cellject	NULL
apparatus	NULL
(	NULL
Eurogentec	NULL
,	NULL
Belgium	NULL
)	NULL
.	NULL

A	NULL
double	NULL
pulse	NULL
was	NULL
applied	NULL
to	NULL
the	NULL
cells	NULL
.	NULL

The	NULL
first	NULL
pulse	NULL
was	NULL
800-1100	NULL
V	NULL
,	NULL
740	NULL
,	NULL
and	NULL
40	NULL
microfarads	NULL
which	NULL
resulted	NULL
in	NULL
a	NULL
tissue	NULL
constant	NULL
of	NULL
800-850	NULL
us	NULL
.	NULL

The	NULL
second	NULL
pulse	NULL
was	NULL
150-250	NULL
V	NULL
,	NULL
740	NULL
,	NULL
with	NULL
a	NULL
capacitance	NULL
of	NULL
2100	NULL
microfarads	NULL
and	NULL
led	NULL
to	NULL
a	NULL
tissue	NULL
constant	NULL
of	NULL
40	NULL
ms.	NULL
All	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
,	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
were	NULL
diluted	NULL
2-fold	NULL
in	NULL
culture	NULL
medium	NULL
18	NULL
h	NULL
prior	NULL
to	NULL
transfection	NULL
.	NULL

Before	NULL
electroporation	NULL
,	NULL
the	NULL
exponentially	NULL
growing	NULL
cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
after	NULL
trypsinization	NULL
if	NULL
required	NULL
(	NULL
adherent	NULL
cells	NULL
)	NULL
and	NULL
resuspended	NULL
at	NULL
25	NULL
X	NULL
10°/ml	NULL
in	NULL
culture	NULL
medium	NULL
for	NULL
cells	NULL
in	NULL
suspension	NULL
and	NULL
at	NULL
10	NULL
%	NULL
10°/ml	NULL
for	NULL
adherent	NULL
cells	NULL
.	NULL

0.4	NULL
ml	NULL
of	NULL
the	NULL
cell	NULL
suspension	NULL
was	NULL
mixed	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
the	NULL
plasmid	NULL
DNA	NULL
plus	NULL
2.5	NULL
ug	NULL
of	NULL
the	NULL
pRSV-CAT	NULL
transfection	NULL
efficiency	NULL
control	NULL
,	NULL
both	NULL
plasmids	NULL
purified	NULL
by	NULL
two	NULL
CsCl	NULL
gradient	NULL
centrifugation	NULL
,	NULL
electroporated	NULL
in	NULL
cuvettes	NULL
with	NULL
a	NULL
0.4-cm	NULL
gap	NULL
between	NULL
electrodes	NULL
,	NULL
and	NULL
rapidly	NULL
diluted	NULL
to	NULL
1.1	NULL
X	NULL
10°	NULL
cells/ml	NULL
in	NULL
culture	NULL
medium	NULL
.	NULL

Cultures	NULL
were	NULL
returned	NULL
to	NULL
37	NULL
°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
for	NULL
18	NULL
h.	NULL
Hela	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
of	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

For	NULL
transfection	NULL
experiments	NULL
,	NULL
Helia	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
1.5	NULL
x	NULL
10°	NULL
cells/100-mm	NULL
Petri	NULL
dish	NULL
and	NULL
cotransfected	NULL
24	NULL
h	NULL
later	NULL
with	NULL
0.5	NULL
ug	NULL
of	NULL
reporter	NULL
plasmid	NULL
and	NULL
the	NULL
indicated	NULL
amounts	NULL
of	NULL
expression	NULL
plasmids	NULL
,	NULL
using	NULL
the	NULL
calcium	NULL
phosphate	NULL
coprecipitation	NULL
method	NULL
(	NULL
26	NULL
)	NULL
.	NULL

When	NULL
the	NULL
activities	NULL
of	NULL
different	NULL
doses	NULL
of	NULL
expression	NULL
plasmids	NULL
were	NULL
compared	NULL
,	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
expression	NULL
vector	NULL
was	NULL
kept	NULL
constant	NULL
by	NULL
addition	NULL
of	NULL
the	NULL
control	NULL
expression	NULL
plasmid	NULL
AEB	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
the	NULL
DNA	NULL
,	NULL
the	NULL
plates	NULL
were	NULL
kept	NULL
at	NULL
37	NULL
°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
for	NULL
20	NULL
h.	NULL
Cell	NULL
medium	NULL
was	NULL
changed	NULL
and	NULL
then	NULL
the	NULL
plates	NULL
were	NULL
left	NULL
undisturbed	NULL
until	NULL
the	NULL
time	NULL
for	NULL
harvest	NULL
24	NULL
h	NULL
later	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
by	NULL
pipetting	NULL
,	NULL
washed	NULL
once	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

Cell	NULL
Extracts	NULL
and	NULL
Luciferase	NULL
Assays-Eighteen	NULL
hours	NULL
following	NULL
transfection	NULL
,	NULL
nonadherent	NULL
cells	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
ice-cold	NULL
phosphate-buffered	NULL
saline	NULL
1	NULL
X	NULL
and	NULL
resuspended	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
)	NULL
.	NULL

Adherent	NULL
cells	NULL
were	NULL
first	NULL
trypsinized	NULL
before	NULL
washing	NULL
the	NULL
cells	NULL
and	NULL
then	NULL
lysed	NULL
after	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

In	NULL
order	NULL
to	NULL
increase	NULL
luciferase	NULL
activity	NULL
(	NULL
up	NULL
to	NULL
20	NULL
%	NULL
)	NULL
in	NULL
cell	NULL
extracts	NULL
,	NULL
cells	NULL
were	NULL
subjected	NULL
to	NULL
one	NULL
cycle	NULL
of	NULL
freezing	NULL
on	NULL
dry	NULL
ice	NULL
after	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
thawed	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
clarified	NULL
from	NULL
insoluble	NULL
material	NULL
(	NULL
debris	NULL
)	NULL
by	NULL
a	NULL
2-min	NULL
centrifugation	NULL
at	NULL
1800	NULL
%	NULL
g	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
transferred	NULL
to	NULL
a	NULL
fresh	NULL
tube	NULL
.	NULL

The	NULL
luciferase	NULL
activity	NULL
in	NULL
the	NULL
supernatant	NULL
*	NULL
Anne	NULL
Gégonne	NULL
,	NULL
R.	NULL
Bosselut	NULL
,	NULL
and	NULL
J.	NULL
Ghysdael	NULL
,	NULL
unpublished	NULL
data	NULL
.	NULL

Regulation	NULL
of	NULL
ye	NULL
Gene	NULL
Promoter	NULL
Activity	NULL
by	NULL
Ets	NULL
Products	NULL
remained	NULL
unaltered	NULL
during	NULL
storage	NULL
for	NULL
several	NULL
days	NULL
at	NULL
-20	NULL
°C	NULL
.	NULL

The	NULL
resulting	NULL
extracts	NULL
were	NULL
then	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
in	NULL
order	NULL
to	NULL
normalize	NULL
the	NULL
transfection	NULL
efficiency	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
butyryl	NULL
coenzyme	NULL
A	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
``	NULL
'	NULL
C-labeled	NULL
chloramphenicol	NULL
(	NULL
ICN	NULL
,	NULL
Orsay	NULL
,	NULL
France	NULL
)	NULL
.	NULL

After	NULL
1	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
,	NULL
the	NULL
butyrylated	NULL
chloramphenicol	NULL
was	NULL
extracted	NULL
with	NULL
2,6,10,14-tetramethylpentadecane/xylenes	NULL
(	NULL
2:1	NULL
,	NULL
v/v	NULL
)	NULL
and	NULL
counted	NULL
in	NULL
a	NULL
scintillation	NULL
counter	NULL
.	NULL

For	NULL
the	NULL
luciferase	NULL
assay	NULL
,	NULL
1-20	NULL
pl	NULL
of	NULL
each	NULL
extract	NULL
depending	NULL
on	NULL
CAT	NULL
assay	NULL
results	NULL
were	NULL
diluted	NULL
into	NULL
QSP	NULL
20-ul	NULL
lysis	NULL
buffer	NULL
and	NULL
mixed	NULL
with	NULL
100	NULL
pl	NULL
of	NULL
ATP	NULL
and	NULL
luciferin	NULL
in	NULL
a	NULL
scintillation	NULL
vial	NULL
.	NULL

After	NULL
a	NULL
7-s	NULL
incubation	NULL
,	NULL
light	NULL
emission	NULL
was	NULL
monitored	NULL
over	NULL
1	NULL
min	NULL
on	NULL
the	NULL
standard	NULL
radioactivity	NULL
channel	NULL
of	NULL
the	NULL
scintillation	NULL
counter	NULL
Tri-Carb	NULL
4000	NULL
(	NULL
United	NULL
Technologies	NULL
,	NULL
Packard	NULL
)	NULL
after	NULL
disabling	NULL
the	NULL
coincidence	NULL
circuit	NULL
.	NULL

Background	NULL
activity	NULL
was	NULL
measured	NULL
with	NULL
lysis	NULL
buffer	NULL
,	NULL
ATP	NULL
,	NULL
and	NULL
luciferin	NULL
and	NULL
ranged	NULL
30,000-60,000	NULL
cpm	NULL
.	NULL

Background	NULL
values	NULL
were	NULL
subtracted	NULL
from	NULL
sample	NULL
values	NULL
.	NULL

RNA	NULL
Preparation-Total	NULL
cellular	NULL
RNA	NULL
was	NULL
prepared	NULL
from	NULL
cells	NULL
using	NULL
the	NULL
guanidine	NULL
thiocyanate	NULL
method	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
then	NULL
electrophoresed	NULL
in	NULL
formaldehyde-denaturing	NULL
agarose	NULL
gels	NULL
and	NULL
subjected	NULL
to	NULL
nylon	NULL
blot	NULL
hybridization	NULL
with	NULL
the	NULL
ye	NULL
chain	NULL
probe	NULL
at	NULL
42°C	NULL
overnight	NULL
.	NULL

Washes	NULL
were	NULL
performed	NULL
in	NULL
2	NULL
x	NULL
SSC	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
60	NULL
°C	NULL
for	NULL
20	NULL
min	NULL
and	NULL
0.2	NULL
x	NULL
SSC	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
60°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

After	NULL
exposure	NULL
of	NULL
the	NULL
autoradiogram	NULL
,	NULL
the	NULL
filters	NULL
were	NULL
stripped	NULL
and	NULL
rehybridized	NULL
to	NULL
an	NULL
actin	NULL
probe	NULL
to	NULL
verify	NULL
both	NULL
quantity	NULL
and	NULL
quality	NULL
of	NULL
RNA	NULL
loadings	NULL
.	NULL

Immunofluorescence-The	NULL
constitutive	NULL
expression	NULL
of	NULL
IL-2Re	NULL
,	NULL
-8	NULL
,	NULL
and	NULL
ye	NULL
chain	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
different	NULL
cell	NULL
lines	NULL
by	NULL
using	NULL
immunofluorescence	NULL
techniques	NULL
.	NULL

Indirect	NULL
immunofluorescence	NULL
using	NULL
the	NULL
murine	NULL
mAb	NULL
341	NULL
,	NULL
directed	NULL
against	NULL
the	NULL
IL2RB	NULL
chain	NULL
(	NULL
Immunotech	NULL
,	NULL
France	NULL
)	NULL
,	NULL
and	NULL
the	NULL
rat	NULL
mAb	NULL
TuGh4	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr.	NULL
K.	NULL
Sugamura	NULL
)	NULL
,	NULL
directed	NULL
against	NULL
the	NULL
IL2Ry	NULL
chain	NULL
(	NULL
28	NULL
)	NULL
,	NULL
was	NULL
performed	NULL
to	NULL
measure	NULL
surface	NULL
expression	NULL
.	NULL

The	NULL
second	NULL
antibodies	NULL
were	NULL
biotin-conjugated	NULL
anti-mouse	NULL
Ig	NULL
(	NULL
Jackson	NULL
,	NULL
West	NULL
Grove	NULL
,	NULL
PA	NULL
)	NULL
and	NULL
biotin-conjugated	NULL
anti-rat	NULL
Ig	NULL
(	NULL
Jackson	NULL
,	NULL
West	NULL
Grove	NULL
)	NULL
with	NULL
mAb	NULL
341	NULL
and	NULL
TuGh4	NULL
,	NULL
respectively	NULL
.	NULL

Both	NULL
second	NULL
antibodies	NULL
were	NULL
revealed	NULL
with	NULL
phycoerythrin-conjugated	NULL
avidin	NULL
(	NULL
Caltag	NULL
,	NULL
San	NULL
Francisco	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
as	NULL
described	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assays	NULL
(	NULL
EMSAs	NULL
)	NULL
-Raji	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
pelleted	NULL
,	NULL
and	NULL
lysed	NULL
by	NULL
resuspension	NULL
in	NULL
4	NULL
volumes	NULL
of	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
0.3	NULL
M	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
1	NULL
%	NULL
aprotinin	NULL
,	NULL
100	NULL
ug/ml	NULL
phenylmethylsulfonyl	NULL
flu-oride	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
centrifuged	NULL
at	NULL
1400	NULL
x	NULL
g	NULL
for	NULL
15	NULL
min	NULL
,	NULL
and	NULL
supernatants	NULL
were	NULL
used	NULL
as	NULL
a	NULL
source	NULL
of	NULL
protein	NULL
for	NULL
DNA	NULL
binding	NULL
experiments	NULL
.	NULL

Oligonucleotide	NULL
probes	NULL
were	NULL
labeled	NULL
by	NULL
filling	NULL
in	NULL
with	NULL
the	NULL
Klenow	NULL
fragment	NULL
of	NULL
DNA	NULL
polymerase	NULL
I	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
a-	NULL
``	NULL
``	NULL
P	NULL
]	NULL
4CTP	NULL
.	NULL

DNA	NULL
binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Competitor	NULL
oligonucleotides	NULL
were	NULL
first	NULL
added	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
and	NULL
then	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
cellular	NULL
extracts	NULL
was	NULL
followed	NULL
by	NULL
an	NULL
incubation	NULL
of	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
started	NULL
when	NULL
the	NULL
probe	NULL
was	NULL
added	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
loaded	NULL
after	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
on	NULL
a	NULL
7.5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
acrylamide/	NULL
bisacrylamide	NULL
ratio	NULL
of	NULL
29:1	NULL
)	NULL
in	NULL
0.25	NULL
x	NULL
TBE	NULL
(	NULL
1	NULL
x	NULL
TBE	NULL
=	NULL
0.089	NULL
m	NULL
Tris	NULL
,	NULL
0.089	NULL
M	NULL
boric	NULL
acid	NULL
,	NULL
2.5	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
8.3	NULL
)	NULL
and	NULL
electrophoresed	NULL
at	NULL
160	NULL
V	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Gels	NULL
were	NULL
fixed	NULL
,	NULL
dried	NULL
,	NULL
and	NULL
exposed	NULL
to	NULL
Kodak	NULL
X-0-Mat	NULL
S	NULL
film	NULL
overnight	NULL
at	NULL
room	NULL
temperature	NULL
using	NULL
an	NULL
intensifying	NULL
screen	NULL
.	NULL

For	NULL
incubation	NULL
with	NULL
serum	NULL
for	NULL
the	NULL
supershift	NULL
assays	NULL
,	NULL
2	NULL
pl	NULL
of	NULL
either	NULL
a	NULL
control	NULL
nonimmune	NULL
serum	NULL
,	NULL
an	NULL
ErbA	NULL
control	NULL
antiserum	NULL
(	NULL
31	NULL
)	NULL
,	NULL
or	NULL
antisera	NULL
specific	NULL
to	NULL
either	NULL
Ets	NULL
1/2	NULL
(	NULL
82	NULL
)	NULL
,	NULL
Fli-1	NULL
(	NULL
383	NULL
)	NULL
,	NULL
GABPa	NULL
and	NULL
-	NULL
$	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr.	NULL
S.	NULL
Mc	NULL
Knight	NULL
)	NULL
,	NULL
Elf-1	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr.	NULL
J.	NULL
M.	NULL
Leiden	NULL
)	NULL
were	NULL
added	NULL
to	NULL
binding	NULL
reactions	NULL
and	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
15	NULL
min	NULL
before	NULL
loading	NULL
the	NULL
gels	NULL
.	NULL

Oligonucleotides	NULL
Used	NULL
for	NULL
EMSAs-Only	NULL
the	NULL
GGAA	NULL
containing	NULL
strand	NULL
of	NULL
the	NULL
oligonucleotide	NULL
is	NULL
shown	NULL
,	NULL
with	NULL
the	NULL
EBS	NULL
core	NULL
underlined	NULL
.	NULL

Every	NULL
oligonucleotide	NULL
includes	NULL
an	NULL
Xhol	NULL
site	NULL
at	NULL
its	NULL
5	NULL
'	NULL
side	NULL
and	NULL
is	NULL
flanked	NULL
by	NULL
Aval	NULL
restriction	NULL
sites	NULL
(	NULL
84	NULL
)	NULL
.	NULL

The	NULL
EBS	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
(	NULL
oligonucleotide	NULL
98	NULL
)	NULL
has	NULL
the	NULL
following	NULL
sequence	NULL
(	NULL
plus	NULL
strand	NULL
)	NULL
:	NULL
5	NULL
TCG	NULL
GGC	NULL
TCG	NULL
AGT	NULL
TCC	NULL
ACC	NULL
GGA	NULL
AGC	NULL
TAT	NULL
C	NULL
3	NULL
'	NULL
and	NULL
is	NULL
flanked	NULL
by	NULL
Xhol	NULL
and	NULL
Aval	NULL
restrictions	NULL
site	NULL
too	NULL
.	NULL

Oligonucleotide	NULL
98	NULL
encompasses	NULL
the	NULL
potential	NULL
Ets	NULL
site	NULL
found	NULL
in	NULL
position	NULL
-68	NULL
of	NULL
the	NULL
human	NULL
yc	NULL
promoter	NULL
.	NULL

Oligonucleotides	NULL
386	NULL
,	NULL
388	NULL
,	NULL
412	NULL
,	NULL
and	NULL
305	NULL
were	NULL
described	NULL
previously	NULL
(	NULL
84	NULL
)	NULL
.	NULL

Oligonucleotide	NULL
386	NULL
is	NULL
an	NULL
optimized	NULL
high	NULL
affinity	NULL
in	NULL
vitro	NULL
binding	NULL
site	NULL
for	NULL
Ets	NULL
proteins	NULL
.	NULL

Oligonucleotide	NULL
388	NULL
is	NULL
derived	NULL
from	NULL
oligonucleotide	NULL
B	NULL
with	NULL
the	NULL
replacement	NULL
A	NULL
-	NULL
>	NULL
T	NULL
in	NULL
the	NULL
EBS	NULL
core	NULL
and	NULL
has	NULL
a	NULL
low	NULL
affinity	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
EIf-1	NULL
.	NULL

Oligonucleotide	NULL
412	NULL
differs	NULL
from	NULL
oligonucleotide	NULL
386	NULL
by	NULL
a	NULL
GG	NULL
-	NULL
CC	NULL
transversion	NULL
at	NULL
positions	NULL
+1	NULL
and	NULL
+2	NULL
in	NULL
the	NULL
EBS	NULL
core	NULL
and	NULL
is	NULL
therefore	NULL
unable	NULL
to	NULL
bind	NULL
Ets	NULL
proteins	NULL
.	NULL

Oligonucleotide	NULL
305	NULL
is	NULL
a	NULL
high	NULL
affinity	NULL
binding	NULL
site	NULL
for	NULL
Pu-1/	NULL
Spi-1	NULL
and	NULL
Spi	NULL
B	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Regulation	NULL
of	NULL
ye	NULL
Gene	NULL
Promoter	NULL
Activity	NULL
by	NULL
Ets	NULL
Products	NULL
<	NULL
_	NULL
ou	NULL
u	NULL
&	NULL
a	NULL
b	NULL
2	NULL
3	NULL
3	NULL
LoS	NULL
a	NULL
o	NULL
a	NULL
5	NULL
$	NULL
o	NULL
a	NULL
x	NULL
3	NULL
2	NULL
R	NULL
a	NULL
d	NULL
5	NULL
$	NULL
.	NULL

$	NULL
2	NULL
8	NULL
a	NULL
a	NULL
A	NULL
a	NULL
m	NULL
s	NULL
S	NULL
>	NULL
v	NULL
A	NULL
£	NULL
ko	NULL
i	NULL
1.8	NULL
kb	NULL
«	NULL
s	NULL
«	NULL
»	NULL
®	NULL
@	NULL
-	NULL
vo	NULL
2.0	NULL
kb	NULL
-	NULL
.	NULL

--	NULL
``	NULL
..	NULL
B	NULL
actin	NULL
B	NULL
1	NULL
203	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8	NULL
a	NULL
10	NULL
1L-2R4	NULL
+	NULL
ad	NULL
a+	NULL
i12-Rp	NULL
£002	NULL
aa	NULL
ad	NULL
Yo	NULL
+	NULL
+o	NULL
-	NULL
44	NULL
4+	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

A	NULL
,	NULL
analysis	NULL
of	NULL
yc	NULL
chain	NULL
transcripts	NULL
in	NULL
various	NULL
hematopoietic	NULL
or	NULL
nonhematopoietic	NULL
cell	NULL
lines	NULL
.	NULL

1	NULL
,	NULL
B-LCL	NULL
;	NULL
2	NULL
,	NULL
Raji	NULL
;	NULL
3	NULL
,	NULL
Jurkat	NULL
;	NULL
4	NULL
,	NULL
IARC	NULL
301.5	NULL
;	NULL
5	NULL
,	NULL
YT	NULL
;	NULL
6	NULL
,	NULL
K562	NULL
;	NULL
7	NULL
,	NULL
DLD-1	NULL
;	NULL
8	NULL
,	NULL
Hep-G2	NULL
;	NULL
9	NULL
and	NULL
10	NULL
,	NULL
fibroblasts	NULL
from	NULL
a	NULL
normal	NULL
subject	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
electrophoresed	NULL
in	NULL
formaldehyde-denaturing	NULL
agarose	NULL
gel	NULL
and	NULL
subjected	NULL
to	NULL
nylon	NULL
blot	NULL
hybridization	NULL
with	NULL
the	NULL
radiolabeled	NULL
yc	NULL
chain	NULL
probe	NULL
.	NULL

Filter	NULL
containing	NULL
nonhematopoietic	NULL
cells	NULL
(	NULL
7-10	NULL
)	NULL
were	NULL
exposed	NULL
for	NULL
a	NULL
longer	NULL
time	NULL
(	NULL
72	NULL
h	NULL
)	NULL
than	NULL
hematopoietic	NULL
cell	NULL
filter	NULL
(	NULL
24	NULL
h	NULL
)	NULL
to	NULL
ensure	NULL
absence	NULL
of	NULL
detectable	NULL
specific	NULL
signal	NULL
.	NULL

After	NULL
exposure	NULL
of	NULL
the	NULL
autoradiogram	NULL
,	NULL
filters	NULL
were	NULL
stripped	NULL
and	NULL
rehybridized	NULL
to	NULL
an	NULL
actin	NULL
probe	NULL
to	NULL
verify	NULL
both	NULL
quantity	NULL
and	NULL
quality	NULL
of	NULL
RNA	NULL
loadings	NULL
.	NULL

B	NULL
,	NULL
membrane	NULL
expression	NULL
of	NULL
human	NULL
IL-2Ra	NULL
,	NULL
-	NULL
,	NULL
and	NULL
yc	NULL
chain	NULL
in	NULL
the	NULL
different	NULL
cell	NULL
lines	NULL
studied	NULL
was	NULL
assessed	NULL
by	NULL
cytofluorimetry	NULL
using	NULL
indirect	NULL
immunofluorescence	NULL
(	NULL
-	NULL
)	NULL
no	NULL
expression	NULL
;	NULL
(	NULL
+	NULL
)	NULL
low	NULL
expression	NULL
;	NULL
(	NULL
++	NULL
)	NULL
high	NULL
expression	NULL
.	NULL

RESULTS	NULL
Cell	NULL
and	NULL
Tissue-specific	NULL
Expression	NULL
of	NULL
the	NULL
ye	NULL
Chain-Expres-sion	NULL
of	NULL
the	NULL
ye	NULL
chain	NULL
was	NULL
determined	NULL
at	NULL
the	NULL
mRNA	NULL
level	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
and	NULL
at	NULL
the	NULL
membrane	NULL
level	NULL
by	NULL
immunofluorescence	NULL
studies	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
a	NULL
variety	NULL
of	NULL
human	NULL
hematopoietic	NULL
cells	NULL
(	NULL
Jurkat	NULL
,	NULL
YT	NULL
,	NULL
IARC	NULL
301.5	NULL
,	NULL
Raji	NULL
,	NULL
BCL	NULL
,	NULL
and	NULL
K562	NULL
)	NULL
and	NULL
nonhematopoietic	NULL
cells	NULL
(	NULL
Hep-G2	NULL
,	NULL
DLD1	NULL
,	NULL
fibro-blasts	NULL
)	NULL
and	NULL
hybridized	NULL
with	NULL
a	NULL
human	NULL
yc	NULL
chain	NULL
probe	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
an	NULL
abundant	NULL
1.8-kilobase	NULL
yc	NULL
transcript	NULL
was	NULL
present	NULL
in	NULL
all	NULL
the	NULL
hematopoietic	NULL
cells	NULL
tested	NULL
and	NULL
was	NULL
absent	NULL
in	NULL
the	NULL
other	NULL
cell	NULL
lines	NULL
or	NULL
tissues	NULL
,	NULL
whereas	NULL
reprobing	NULL
the	NULL
same	NULL
blot	NULL
with	NULL
a	NULL
B-actin	NULL
probe	NULL
detected	NULL
high	NULL
levels	NULL
of	NULL
B-actin	NULL
transcript	NULL
in	NULL
all	NULL
the	NULL
samples	NULL
.	NULL

Among	NULL
the	NULL
yc	NULL
(	NULL
+	NULL
)	NULL
cell	NULL
lines	NULL
,	NULL
membrane	NULL
expression	NULL
of	NULL
the	NULL
yc	NULL
chain	NULL
was	NULL
detected	NULL
only	NULL
on	NULL
the	NULL
B	NULL
lymphoblastoid	NULL
cells	NULL
(	NULL
BCL	NULL
and	NULL
Raji	NULL
)	NULL
,	NULL
the	NULL
natural	NULL
killer-like	NULL
cell	NULL
YT	NULL
,	NULL
and	NULL
the	NULL
T	NULL
cells	NULL
(	NULL
IARC	NULL
301.5	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

To	NULL
try	NULL
to	NULL
elucidate	NULL
the	NULL
elements	NULL
critical	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
yc	NULL
gene	NULL
,	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
region	NULL
upstream	NULL
of	NULL
the	NULL
initiation	NULL
codon	NULL
was	NULL
analyzed	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
using	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
in	NULL
transient	NULL
tranfection	NULL
assay	NULL
.	NULL

Important	NULL
Tissue-specific	NULL
cis-Regulatory	NULL
Elements	NULL
Are	NULL
Located	NULL
within	NULL
-90/+34	NULL
bp	NULL
of	NULL
the	NULL
ye	NULL
Gene	NULL
Transcription	NULL
Start	NULL
Site-Cloning	NULL
and	NULL
sequencing	NULL
of	NULL
1595	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
major	NULL
transcription	NULL
site	NULL
allowed	NULL
the	NULL
identification	NULL
of	NULL
18	NULL
GGAA	NULL
or	NULL
GGAT	NULL
(	NULL
35	NULL
)	NULL
sequences	NULL
typical	NULL
of	NULL
those	NULL
recognized	NULL
by	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

To	NULL
delineate	NULL
the	NULL
cis-acting	NULL
elements	NULL
regulating	NULL
yc	NULL
expression	NULL
,	NULL
we	NULL
first	NULL
examined	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
full-length	NULL
promoter	NULL
(	NULL
-1053/+34	NULL
)	NULL
(	NULL
+1	NULL
corresponds	NULL
to	NULL
the	NULL
major	NULL
transcription	NULL
site	NULL
)	NULL
and	NULL
of	NULL
a	NULL
series	NULL
of	NULL
nested	NULL
5'-deletion	NULL
constructs	NULL
derived	NULL
in	NULL
the	NULL
Raji	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
-1053/	NULL
+34	NULL
construct	NULL
was	NULL
460-fold	NULL
more	NULL
active	NULL
than	NULL
the	NULL
pGI2	NULL
basic	NULL
promoterless	NULL
control	NULL
vector	NULL
in	NULL
the	NULL
Raji	NULL
cell	NULL
line	NULL
to	NULL
induce	NULL
luciferase	NULL
activity	NULL
.	NULL

Similar	NULL
activity	NULL
was	NULL
detected	NULL
when	NULL
assessing	NULL
14851	NULL
the	NULL
five	NULL
promoter	NULL
constructs	NULL
containing	NULL
a	NULL
promoter	NULL
fragment	NULL
starting	NULL
at	NULL
positions	NULL
-1053	NULL
,	NULL
-754	NULL
,	NULL
-292	NULL
,	NULL
-166	NULL
,	NULL
and	NULL
-117	NULL
bp	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
the	NULL
5'-flanking	NULL
region	NULL
,	NULL
whereas	NULL
expression	NULL
driven	NULL
by	NULL
the	NULL
construct	NULL
containing	NULL
only	NULL
the	NULL
last	NULL
-90	NULL
bp	NULL
of	NULL
the	NULL
5'-flank	NULL
displayed	NULL
a	NULL
45	NULL
%	NULL
reduction	NULL
in	NULL
activity	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
largest	NULL
construct	NULL
.	NULL

A	NULL
further	NULL
deletion	NULL
of	NULL
46	NULL
bp	NULL
(	NULL
-44/+34	NULL
)	NULL
totally	NULL
abolished	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
the	NULL
yc	NULL
promoter	NULL
gene	NULL
contains	NULL
a	NULL
critical	NULL
regulatory	NULL
region	NULL
between	NULL
nucleotide	NULL
positions	NULL
-90	NULL
and	NULL
-44	NULL
which	NULL
is	NULL
required	NULL
for	NULL
promoter	NULL
activity	NULL
in	NULL
the	NULL
Raji	NULL
cell	NULL
line	NULL
.	NULL

Since	NULL
ye	NULL
chain	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
hematopoietic	NULL
cells	NULL
,	NULL
we	NULL
next	NULL
analyzed	NULL
the	NULL
specificity	NULL
of	NULL
our	NULL
yc	NULL
promoter	NULL
constructs	NULL
in	NULL
other	NULL
hematopoietic	NULL
and	NULL
nonhematopoietic	NULL
cell	NULL
lines	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
the	NULL
-754/+34	NULL
to	NULL
-90/+34	NULL
constructs	NULL
were	NULL
also	NULL
active	NULL
after	NULL
transfection	NULL
in	NULL
a	NULL
natural	NULL
killer-like	NULL
cell	NULL
line	NULL
(	NULL
YT	NULL
)	NULL
and	NULL
in	NULL
a	NULL
myelogenous	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
K562	NULL
)	NULL
and	NULL
in	NULL
two	NULL
different	NULL
T	NULL
cell	NULL
lines	NULL
(	NULL
Jurkat	NULL
and	NULL
IARC	NULL
301.5	NULL
)	NULL
,	NULL
but	NULL
they	NULL
were	NULL
poorly	NULL
or	NULL
not	NULL
active	NULL
at	NULL
all	NULL
after	NULL
transfection	NULL
in	NULL
nonhematopoietic	NULL
tissues	NULL
or	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
primary	NULL
fibroblasts	NULL
or	NULL
fibroblasts	NULL
transformed	NULL
by	NULL
SV40	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
in	NULL
the	NULL
hepatoma	NULL
cell	NULL
line	NULL
Hep-G2	NULL
or	NULL
in	NULL
the	NULL
human	NULL
colorectal	NULL
adenocarcinoma	NULL
cell	NULL
line	NULL
DLD-1	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
conclude	NULL
that	NULL
expression	NULL
of	NULL
these	NULL
promoter	NULL
constructs	NULL
exhibited	NULL
cell-type	NULL
specificity	NULL
.	NULL

Functional	NULL
Role	NULL
of	NULL
the	NULL
Two	NULL
EBS	NULL
Present	NULL
in	NULL
the	NULL
-90	NULL
to	NULL
-44	NULL
yc	NULL
Promoter	NULL
Region-Since	NULL
the	NULL
-90/+34	NULL
promoter	NULL
construct	NULL
(	NULL
G1bS8	NULL
)	NULL
was	NULL
shown	NULL
to	NULL
exhibit	NULL
significant	NULL
promoter	NULL
activity	NULL
in	NULL
all	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
construct	NULL
in	NULL
further	NULL
detail	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
human	NULL
and	NULL
the	NULL
murine	NULL
yc	NULL
chain	NULL
promoter	NULL
in	NULL
this	NULL
region	NULL
identified	NULL
numerous	NULL
stretches	NULL
of	NULL
homology	NULL
shared	NULL
by	NULL
both	NULL
receptor	NULL
promoters	NULL
,	NULL
which	NULL
may	NULL
represent	NULL
sites	NULL
essential	NULL
for	NULL
activity	NULL
.	NULL

Alignment	NULL
of	NULL
the	NULL
flanking	NULL
sequence	NULL
of	NULL
the	NULL
human	NULL
gene	NULL
with	NULL
the	NULL
one	NULL
of	NULL
the	NULL
mouse	NULL
genes	NULL
revealed	NULL
two	NULL
GGAA	NULL
motifs	NULL
typical	NULL
of	NULL
the	NULL
core	NULL
of	NULL
DNA	NULL
binding	NULL
sites	NULL
recognized	NULL
by	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
proteins	NULL
(	NULL
15	NULL
,	NULL
35	NULL
)	NULL
in	NULL
the	NULL
region	NULL
between	NULL
-90	NULL
and	NULL
-44	NULL
in	NULL
the	NULL
promoter	NULL
at	NULL
position	NULL
-68/65	NULL
and	NULL
-53/-50	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
the	NULL
two	NULL
putative	NULL
EBS	NULL
at	NULL
-68	NULL
and	NULL
-53	NULL
,	NULL
we	NULL
prepared	NULL
a	NULL
series	NULL
of	NULL
additional	NULL
promoter	NULL
constructs	NULL
.	NULL

The	NULL
H4	NULL
,	NULL
J13	NULL
,	NULL
and	NULL
DM	NULL
constructs	NULL
are	NULL
identical	NULL
to	NULL
the	NULL
-90/+34	NULL
G1bS	NULL
construct	NULL
except	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
transversion	NULL
of	NULL
the	NULL
core	NULL
GG	NULL
dinucleotide	NULL
in	NULL
either	NULL
the	NULL
first	NULL
(	NULL
-68/H4	NULL
)	NULL
or	NULL
in	NULL
the	NULL
second	NULL
(	NULL
-53/J13	NULL
)	NULL
or	NULL
both	NULL
(	NULL
DM	NULL
)	NULL
first	NULL
and	NULL
second	NULL
putative	NULL
EBS	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
then	NULL
transiently	NULL
transfected	NULL
in	NULL
the	NULL
Raji	NULL
and	NULL
Jurkat	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
promoter	NULL
construct	NULL
containing	NULL
the	NULL
mutation	NULL
at	NULL
the	NULL
first	NULL
EBS	NULL
(	NULL
H4	NULL
)	NULL
or	NULL
at	NULL
both	NULL
sites	NULL
(	NULL
DM	NULL
)	NULL
showed	NULL
background	NULL
luciferase	NULL
activity	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
,	NULL
whereas	NULL
a	NULL
similar	NULL
luciferase	NULL
activity	NULL
as	NULL
the	NULL
parental	NULL
reporter	NULL
plasmid	NULL
(	NULL
G1bS	NULL
)	NULL
was	NULL
not	NULL
modified	NULL
when	NULL
the	NULL
second	NULL
site	NULL
(	NULL
J13	NULL
)	NULL
only	NULL
was	NULL
mutated	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

These	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
the	NULL
EBS	NULL
present	NULL
at	NULL
position	NULL
-68	NULL
is	NULL
a	NULL
determinant	NULL
for	NULL
the	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
yc	NULL
chain	NULL
gene	NULL
in	NULL
Jurkat	NULL
and	NULL
Raji	NULL
cells	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
DNA-Protein	NULL
Complexes	NULL
Associated	NULL
with	NULL
the	NULL
Functional	NULL
EBS	NULL
Present	NULL
in	NULL
the	NULL
Basal	NULL
Promoter	NULL
Region	NULL
of	NULL
the	NULL
ye	NULL
Gene-To	NULL
analyze	NULL
whether	NULL
extracts	NULL
from	NULL
Raji	NULL
cells	NULL
contain	NULL
DNA	NULL
binding	NULL
proteins	NULL
able	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
first	NULL
EBS	NULL
at	NULL
-68/-65	NULL
,	NULL
EMSAs	NULL
were	NULL
performed	NULL
using	NULL
a	NULL
28-mer	NULL
oligonucleotide	NULL
probe	NULL
encompassing	NULL
this	NULL
putative	NULL
EBS	NULL
.	NULL

Several	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
observed	NULL
in	NULL
this	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
;	NULL
four	NULL
of	NULL
these	NULL
complexes	NULL
correspond	NULL
to	NULL
specific	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
probe	NULL
since	NULL
they	NULL
were	NULL
competed	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
an	NULL
unlabeled	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
probe	NULL
98	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
but	NULL
not	NULL
by	NULL
a	NULL
nonspecific	NULL
oligonucleotide	NULL
competitor	NULL
(	NULL
oligo	NULL
412	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

The	NULL
nature	NULL
of	NULL
the	NULL
nuclear	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
probe	NULL
were	NULL
next	NULL
studied	NULL
by	NULL
EMSAs	NULL
using	NULL
competitor	NULL
oligonucleotides	NULL
with	NULL
different	NULL
binding	NULL
activity	NULL
for	NULL
members	NULL
of	NULL
the	NULL
Ets	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
14852	NULL
Regulation	NULL
of	NULL
ye	NULL
Gene	NULL
Promoter	NULL
Activity	NULL
by	NULL
Ets	NULL
Products	NULL
A	NULL
B	NULL
+1595	NULL
1490-1419	NULL
1052	NULL
928	NULL
788	NULL
.	NULL

441	NULL
-479	NULL
966	NULL
+241	NULL
-68	NULL
|	NULL
134	NULL
l	NULL
ims	NULL
780	NULL
-	NULL
605	NULL
-	NULL
466	NULL
t	NULL
lapa	NULL
4	NULL
)	NULL
)	NULL
iga	NULL
!	NULL

1	NULL
897	NULL
1	NULL
I	NULL
L|	NULL
|	NULL
I	NULL
1	NULL
1	NULL
1	NULL
ti	NULL
|	NULL
J	NULL
-1053/+34	NULL
--	NULL
t	NULL
+	NULL
--	NULL
-u	NULL
t	NULL
bid	NULL
d	NULL
>	NULL
~754/+34	NULL
L——	NULL
``	NULL
—|—1-rl—|——	NULL
Be	NULL
33	NULL
E	NULL
-292/+34	NULL
L—g—H—1—	NULL
$	NULL
3	NULL
§	NULL
8	NULL
~166/+34	NULL
‘	NULL
—H—+—	NULL
3	NULL
f	NULL
v4	NULL
11734	NULL
L|—|—	NULL
g	NULL
3	NULL
10d	NULL
-t-441134	NULL
L	NULL
-1053/+34	NULL
154/34	NULL
-292/+34	NULL
-166/+34	NULL
-117434	NULL
-90/+34	NULL
-44/134	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

A	NULL
,	NULL
schematic	NULL
diagram	NULL
of	NULL
the	NULL
ye	NULL
-1595/+34	NULL
region	NULL
showing	NULL
locations	NULL
of	NULL
core	NULL
sequence	NULL
GGA	NULL
(	NULL
A/T	NULL
)	NULL
(	NULL
C	NULL
]	NULL
)	NULL
for	NULL
putative	NULL
Ets	NULL
binding	NULL
sites	NULL
.	NULL

B	NULL
,	NULL
deletion	NULL
analysis	NULL
of	NULL
the	NULL
yc	NULL
promoter	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

Luciferase	NULL
reporter	NULL
gene	NULL
activity	NULL
,	NULL
corrected	NULL
for	NULL
transfection	NULL
efficiency	NULL
,	NULL
is	NULL
expressed	NULL
as	NULL
fold	NULL
activity	NULL
above	NULL
the	NULL
background	NULL
activity	NULL
conferred	NULL
by	NULL
the	NULL
promoterless	NULL
control	NULL
plasmid	NULL
pGI2	NULL
basic	NULL
in	NULL
untreated	NULL
Raji	NULL
cells	NULL
.	NULL

The	NULL
different	NULL
constructions	NULL
used	NULL
in	NULL
transfection	NULL
assays	NULL
are	NULL
shown	NULL
at	NULL
the	NULL
bottom	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
are	NULL
the	NULL
average	NULL
of	NULL
two	NULL
simultaneously	NULL
performed	NULL
duplicated	NULL
experiments	NULL
.	NULL

A	NULL
second	NULL
set	NULL
of	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
yielded	NULL
similar	NULL
results	NULL
.	NULL

500	NULL
400	NULL
300	NULL
200	NULL
Relative	NULL
luciferase	NULL
activity	NULL
(	NULL
fold	NULL
above	NULL
background	NULL
)	NULL
100	NULL
~754/+34	NULL
(	NULL
+34	NULL
/+34	NULL
/+34	NULL
~754/+34	NULL
+34	NULL
+34	NULL
+34	NULL
/+34	NULL
-9	NULL
``	NULL
44	NULL
,	NULL
``	NULL
A1	NULL
``	NULL
754/+34	NULL
119	NULL
,	NULL
``	NULL
44/134	NULL
y	NULL
/	NULL
f	NULL
y	NULL
has	NULL
[	NULL
/	NULL
-754/+34	NULL
A17	NULL
,	NULL
90/134	NULL
-754/+34	NULL
144	NULL
/	NULL
a	NULL
I	NULL
[	NULL
stl	NULL
sa	NULL
H	NULL
>	NULL
7	NULL
o	NULL
]	NULL
JURKAT	NULL
Hep-G2	NULL
s	NULL
9	NULL
1	NULL
.	NULL

Fibroblasts	NULL
301.5	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Deletion	NULL
analysis	NULL
of	NULL
the	NULL
yc	NULL
promoter	NULL
in	NULL
different	NULL
cell	NULL
lines	NULL
.	NULL

Luciferase	NULL
reporter	NULL
gene	NULL
activity	NULL
,	NULL
corrected	NULL
for	NULL
transfection	NULL
efficiency	NULL
,	NULL
is	NULL
expressed	NULL
as	NULL
fold	NULL
activity	NULL
above	NULL
the	NULL
background	NULL
activity	NULL
conferred	NULL
by	NULL
the	NULL
promoterless	NULL
control	NULL
plasmid	NULL
pGI2	NULL
basic	NULL
in	NULL
untreated	NULL
K562	NULL
,	NULL
YT	NULL
,	NULL
IARC	NULL
301.5	NULL
,	NULL
Jurkat	NULL
,	NULL
Hep-G2	NULL
,	NULL
DLD-1	NULL
,	NULL
and	NULL
fibroblastoid	NULL
cells	NULL
.	NULL

The	NULL
portions	NULL
of	NULL
the	NULL
yc	NULL
chain	NULL
gene	NULL
and	NULL
cell	NULL
lines	NULL
used	NULL
in	NULL
each	NULL
transfection	NULL
assays	NULL
are	NULL
shown	NULL
at	NULL
the	NULL
bottom	NULL
.	NULL

Each	NULL
histogram	NULL
represents	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
transfection	NULL
experiments	NULL
.	NULL

family	NULL
(	NULL
34	NULL
)	NULL
.	NULL

When	NULL
used	NULL
as	NULL
a	NULL
competitor	NULL
,	NULL
an	NULL
oligonucleotide	NULL
(	NULL
oligo	NULL
386	NULL
)	NULL
known	NULL
to	NULL
bind	NULL
all	NULL
of	NULL
the	NULL
Ets	NULL
proteins	NULL
totally	NULL
abolished	NULL
formation	NULL
of	NULL
the	NULL
four	NULL
DNA-protein	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
formation	NULL
of	NULL
all	NULL
these	NULL
complexes	NULL
is	NULL
likely	NULL
to	NULL
involve	NULL
members	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
.	NULL

Almost	NULL
complete	NULL
inhibition	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
four	NULL
complexes	NULL
was	NULL
also	NULL
observed	NULL
with	NULL
an	NULL
oligonucleotide	NULL
(	NULL
oligo	NULL
388	NULL
)	NULL
differing	NULL
from	NULL
oligo	NULL
386	NULL
only	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
GGAT	NULL
core	NULL
instead	NULL
of	NULL
GGAA	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

This	NULL
substitution	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
specifically	NULL
affect	NULL
binding	NULL
of	NULL
Elf-1	NULL
,	NULL
an	NULL
Ets	NULL
family	NULL
member	NULL
expressed	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
Elf-1	NULL
is	NULL
unlikely	NULL
to	NULL
represent	NULL
a	NULL
major	NULL
component	NULL
of	NULL
these	NULL
complexes	NULL
.	NULL

Finally	NULL
,	NULL
Spi	NULL
First	NULL
putative	NULL
Second	NULL
putative	NULL
EBS	NULL
EBS	NULL
-68	NULL
-53	NULL
Human	NULL
_	NULL
TTTCCACC	NULL
|GGAA	NULL
|GCTATGACA-GA	NULL
|GGAA	NULL
|	NULL
ACGTGT	NULL
Mouse	NULL
_	NULL
TTTCCACC	NULL
|GGAA	NULL
|GCTACGACAAAA	NULL
]	NULL
GGAAl	NULL
ATGTAT	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
yc	NULL
promoter	NULL
regions	NULL
.	NULL

Sequence	NULL
of	NULL
the	NULL
human	NULL
(	NULL
Noguchi	NULL
et	NULL
al	NULL
.	NULL

(	NULL
4	NULL
)	NULL
)	NULL
and	NULL
murine	NULL
(	NULL
DiS-anto	NULL
ef	NULL
al	NULL
.	NULL

(	NULL
11	NULL
)	NULL
)	NULL
5'-upstream	NULL
sequence	NULL
is	NULL
compared	NULL
using	NULL
the	NULL
Gene	NULL
Jockey	NULL
program	NULL
.	NULL

Sequences	NULL
are	NULL
numbered	NULL
relative	NULL
to	NULL
the	NULL
major	NULL
transcription	NULL
start	NULL
site	NULL
of	NULL
the	NULL
human	NULL
gene	NULL
.	NULL

Two	NULL
GGAA	NULL
purine-rich	NULL
motifs	NULL
,	NULL
typical	NULL
of	NULL
those	NULL
recognized	NULL
by	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
are	NULL
boxed	NULL
in	NULL
each	NULL
sequence	NULL
.	NULL

1/Pu-1	NULL
appears	NULL
to	NULL
be	NULL
absent	NULL
from	NULL
these	NULL
complexes	NULL
since	NULL
an	NULL
oligonucleotide	NULL
(	NULL
oligo	NULL
305	NULL
)	NULL
which	NULL
efficiently	NULL
binds	NULL
this	NULL
protein	NULL
was	NULL
found	NULL
unable	NULL
to	NULL
compete	NULL
complex	NULL
formation	NULL
in	NULL
the	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
)	NULL
.	NULL

Binding	NULL
patterns	NULL
and	NULL
binding	NULL
competitions	NULL
observed	NULL
using	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
same	NULL
labeled	NULL
probe	NULL
98	NULL
were	NULL
undistinguishable	NULL
from	NULL
those	NULL
seen	NULL
with	NULL
Raji	NULL
nuclear	NULL
extracts	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
strongly	NULL
suggested	NULL
that	NULL
members	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
were	NULL
involved	NULL
in	NULL
the	NULL
complexes	NULL
observed	NULL
.	NULL

Further	NULL
identification	NULL
of	NULL
the	NULL
various	NULL
Ets	NULL
protein	NULL
members	NULL
bound	NULL
to	NULL
the	NULL
-68	NULL
to	NULL
-54	NULL
promoter	NULL
region	NULL
was	NULL
performed	NULL
by	NULL
supershift	NULL
assays	NULL
using	NULL
specific	NULL
antibodies	NULL
.	NULL

In	NULL
EMSAs	NULL
using	NULL
either	NULL
Raji	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
or	NULL
Jurkat	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
labeled	NULL
probe	NULL
98	NULL
,	NULL
a	NULL
slower	NULL
migrating	NULL
supershifted	NULL
complex	NULL
was	NULL
observed	NULL
using	NULL
an	NULL
antiserum	NULL
specific	NULL
for	NULL
GABPa	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

The	NULL
appearance	NULL
of	NULL
this	NULL
supershifted	NULL
band	NULL
was	NULL
accompanied	NULL
by	NULL
the	NULL
complete	NULL
disappearance	NULL
of	NULL
the	NULL
major	NULL
upper	NULL
complex	NULL
C1	NULL
and	NULL
of	NULL
most	NULL
of	NULL
the	NULL
faster	NULL
migrating	NULL
complex	NULL
C4	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
GABPa	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
these	NULL
complexes	NULL
.	NULL

The	NULL
same	NULL
complexes	NULL
were	NULL
also	NULL
supershifted	NULL
when	NULL
an	NULL
anti-GABPB	NULL
was	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

GABPS	NULL
is	NULL
a	NULL
Notch-related	NULL
non-Ets	NULL
protein	NULL
that	NULL
exists	NULL
in	NULL
cells	NULL
as	NULL
a	NULL
stable	NULL
heterodimeric	NULL
complex	NULL
with	NULL
the	NULL
GABPa	NULL
,	NULL
to	NULL
form	NULL
GABP	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Only	NULL
a	NULL
very	NULL
faint	NULL
supershifted	NULL
band	NULL
was	NULL
observed	NULL
after	NULL
addition	NULL
of	NULL
a	NULL
monoclonal	NULL
antibody	NULL
specific	NULL
to	NULL
Elf-1	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
but	NULL
it	NULL
is	NULL
unclear	NULL
which	NULL
of	NULL
the	NULL
C2	NULL
to	NULL
C4	NULL
complexes	NULL
were	NULL
affected	NULL
.	NULL

No	NULL
supershifted	NULL
bands	NULL
were	NULL
observed	NULL
with	NULL
antibodies	NULL
specific	NULL
for	NULL
Spil/Pu-1	NULL
,	NULL
Etsl	NULL
,	NULL
Ets2	NULL
,	NULL
Flil	NULL
,	NULL
or	NULL
a	NULL
control	NULL
Erb-A	NULL
antiserum	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
10	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Regulation	NULL
of	NULL
ye	NULL
Gene	NULL
Promoter	NULL
Activity	NULL
by	NULL
Ets	NULL
Products	NULL
600	NULL
500	NULL
7	NULL
400	NULL
300	NULL
7	NULL
200	NULL
7	NULL
Relative	NULL
luciferase	NULL
activity	NULL
(	NULL
fold	NULL
above	NULL
background	NULL
)	NULL
100	NULL
JURKAT	NULL
4	NULL
-754/34	NULL
{	NULL
5.2.5	NULL
~1053/4+34	NULL
~292/+34	NULL
+166/+34	NULL
+117/4+34	NULL
7	NULL
+90/4+34	NULL
7	NULL
~44/434	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Effect	NULL
of	NULL
EBS	NULL
core	NULL
mutations	NULL
on	NULL
basal	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
yc	NULL
gene	NULL
.	NULL

The	NULL
-90/+34	NULL
construct	NULL
and	NULL
its	NULL
mutated	NULL
variants	NULL
at	NULL
the	NULL
first	NULL
EBS	NULL
site	NULL
(	NULL
H4	NULL
)	NULL
,	NULL
second	NULL
EBS	NULL
site	NULL
(	NULL
J13	NULL
)	NULL
,	NULL
and	NULL
both	NULL
EBS	NULL
sites	NULL
(	NULL
DM	NULL
)	NULL
were	NULL
transfected	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
in	NULL
Raji	NULL
(	NULL
C	NULL
)	NULL
and	NULL
Jurkat	NULL
(	NULL
#	NULL
)	NULL
cells	NULL
.	NULL

Results	NULL
are	NULL
the	NULL
average	NULL
of	NULL
two	NULL
independent	NULL
transfection	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
.	NULL

Moji	NULL
nuclear	NULL
+	NULL
+	NULL
extract	NULL
to	NULL
g	NULL
ko	NULL
d	NULL
dea	NULL
Compatitor	NULL
-	NULL
-	NULL
98	NULL
386	NULL
358	NULL
412	NULL
3337	NULL
x10	NULL
so	NULL
-	NULL
k19	NULL
Xso	NULL
|	NULL
kie	NULL
xse	NULL
x50	NULL
Yio	NULL
Ans	NULL
I	NULL
ane	NULL
Por	NULL
B	NULL
40	NULL
50060070	NULL
80	NULL
%	NULL
10	NULL
dI	NULL
Ace	NULL
2m	NULL
+8	NULL
cn	NULL
--	NULL
-	NULL
-W	NULL
bood	NULL
foud	NULL
C2	NULL
$	NULL
==t	NULL
W	NULL
bud	NULL
bx	NULL
C4	NULL
--	NULL
t	NULL
Free	NULL
probe	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

EMSAs	NULL
of	NULL
Raji	NULL
nuclear	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
98	NULL
sequence	NULL
.	NULL

100	NULL
fmol	NULL
of	NULL
the	NULL
radiolabeled	NULL
oligonucleotide	NULL
98	NULL
prepared	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
were	NULL
incubated	NULL
with	NULL
no	NULL
nuclear	NULL
extract	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
or	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
uninduced	NULL
Raji	NULL
cells	NULL
(	NULL
Zanes	NULL
2-11	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
performed	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
10	NULL
or	NULL
50	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
respective	NULL
unlabeled	NULL
oligonucleotide	NULL
as	NULL
indicated	NULL
.	NULL

At	NULL
least	NULL
four	NULL
complexes	NULL
can	NULL
be	NULL
detected	NULL
and	NULL
are	NULL
marked	NULL
with	NULL
arrows	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
complexes	NULL
C1	NULL
and	NULL
C4	NULL
result	NULL
from	NULL
DNA	NULL
binding	NULL
by	NULL
GABP	NULL
and	NULL
most	NULL
probably	NULL
correspond	NULL
to	NULL
the	NULL
binding	NULL
of	NULL
distinct	NULL
heteromeric	NULL
forms	NULL
of	NULL
GABP	NULL
(	NULL
86	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
minor	NULL
C2	NULL
and	NULL
C3	NULL
complexes	NULL
display	NULL
a	NULL
DNA	NULL
binding	NULL
specificity	NULL
indistinguishable	NULL
from	NULL
that	NULL
of	NULL
Ets	NULL
proteins	NULL
and	NULL
yet	NULL
were	NULL
not	NULL
supershifted	NULL
by	NULL
available	NULL
antibodies	NULL
to	NULL
a	NULL
panel	NULL
of	NULL
Ets	NULL
proteins	NULL
,	NULL
these	NULL
complexes	NULL
are	NULL
likely	NULL
to	NULL
result	NULL
from	NULL
binding	NULL
of	NULL
members	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
other	NULL
than	NULL
Ets1	NULL
,	NULL
Ets2	NULL
,	NULL
Fli1	NULL
,	NULL
GABP	NULL
,	NULL
EIf-1	NULL
,	NULL
and	NULL
Spil/Pu-1	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
-+34	NULL
ye	NULL
Promoter	NULL
Construct	NULL
by	NULL
GABP-To	NULL
analyze	NULL
the	NULL
ability	NULL
of	NULL
several	NULL
Ets	NULL
proteins	NULL
to	NULL
activate	NULL
the	NULL
yc	NULL
promoter	NULL
,	NULL
the	NULL
-90/+34	NULL
promoter	NULL
construct	NULL
(	NULL
G1bS	NULL
)	NULL
was	NULL
cotransfected	NULL
,	NULL
together	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
for	NULL
either	NULL
GABPa	NULL
+	NULL
B	NULL
,	NULL
or	NULL
EIf-1	NULL
or	NULL
Ets-1	NULL
into	NULL
Hela	NULL
cells	NULL
.	NULL

While	NULL
we	NULL
found	NULL
no	NULL
evidence	NULL
of	NULL
transactivation	NULL
of	NULL
the	NULL
-90/	NULL
14853	NULL
Raji	NULL
nuclear	NULL
extract	NULL
~	NULL
~	NULL
~	NULL
~	NULL
~	NULL
+	NULL
+0	NULL
+	NULL
0+	NULL
+	NULL
Antiserum	NULL
GABP	NULL
GABP	NULL
Ei	NULL
EibA	NULL
GABP	NULL
GABP	NULL
Ell	NULL
ErpA	NULL
a	NULL
B	NULL
w	NULL
$	NULL
Lane	NULL
1	NULL
20	NULL
80	NULL
4	NULL
5	NULL
6	NULL
70	NULL
80	NULL
9	NULL
10	NULL
#	NULL
»	NULL
ﬁ-	NULL
inlu	NULL
'	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Effect	NULL
of	NULL
antibodies	NULL
to	NULL
known	NULL
Ets	NULL
members	NULL
on	NULL
the	NULL
different	NULL
complexes	NULL
.	NULL

Supershifts	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
with	NULL
the	NULL
radiolabeled	NULL
98	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
which	NULL
was	NULL
added	NULL
to	NULL
no	NULL
nuclear	NULL
extract	NULL
(	NULL
ane	NULL
5	NULL
)	NULL
or	NULL
nuclear	NULL
extract	NULL
from	NULL
Raji	NULL
cells	NULL
(	NULL
Zanes	NULL
6-10	NULL
)	NULL
,	NULL
preincubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
with	NULL
2	NULL
pl	NULL
of	NULL
polyclonal	NULL
antisera	NULL
against	NULL
GABP	NULL
«	NULL
(	NULL
Zane	NULL
7	NULL
)	NULL
,	NULL
GABPB	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
and	NULL
ErbA	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
and	NULL
1	NULL
ul	NULL
of	NULL
monoclonal	NULL
antiserum	NULL
against	NULL
Elf-1	NULL
(	NULL
Zane	NULL
9	NULL
)	NULL
.	NULL

+34	NULL
construct	NULL
by	NULL
Elf-1	NULL
and	NULL
Ets-1	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
expression	NULL
of	NULL
GABP	NULL
was	NULL
found	NULL
to	NULL
activate	NULL
this	NULL
promoter	NULL
construct	NULL
.	NULL

Transactivation	NULL
by	NULL
GABP	NULL
is	NULL
dependent	NULL
upon	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
EBS	NULL
centered	NULL
at	NULL
nucleotide	NULL
-67	NULL
since	NULL
a	NULL
promoter	NULL
construct	NULL
(	NULL
H4	NULL
)	NULL
harboring	NULL
a	NULL
GG	NULL
to	NULL
CC	NULL
transversion	NULL
,	NULL
which	NULL
inhibits	NULL
formation	NULL
of	NULL
the	NULL
GABP	NULL
complex	NULL
,	NULL
in	NULL
this	NULL
EBS	NULL
core	NULL
sequence	NULL
failed	NULL
to	NULL
respond	NULL
to	NULL
GABP	NULL
in	NULL
cotransfection	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
maximal	NULL
activation	NULL
by	NULL
GABP	NULL
appeared	NULL
to	NULL
require	NULL
complex	NULL
formation	NULL
between	NULL
the	NULL
a	NULL
and	NULL
B	NULL
subunit	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
since	NULL
transfection	NULL
of	NULL
the	NULL
GABPa	NULL
subunit	NULL
alone	NULL
did	NULL
not	NULL
result	NULL
in	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
from	NULL
these	NULL
experiments	NULL
that	NULL
the	NULL
heteromeric	NULL
forms	NULL
of	NULL
GABP	NULL
transactivate	NULL
the	NULL
yc	NULL
promoter	NULL
region	NULL
through	NULL
binding	NULL
to	NULL
the	NULL
EBS	NULL
(	NULL
GGAA	NULL
)	NULL
element	NULL
centered	NULL
at	NULL
position	NULL
-67	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
work	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
5	NULL
regulatory	NULL
elements	NULL
of	NULL
the	NULL
yc	NULL
gene	NULL
essential	NULL
for	NULL
tissue-specific	NULL
expression	NULL
of	NULL
this	NULL
gene	NULL
.	NULL

We	NULL
show	NULL
that	NULL
a	NULL
1053-bp	NULL
fragment	NULL
5	NULL
'	NULL
to	NULL
the	NULL
yc	NULL
initiation	NULL
site	NULL
mediates	NULL
promoter	NULL
activity	NULL
in	NULL
all	NULL
the	NULL
hematopoietic	NULL
cells	NULL
studied	NULL
,	NULL
whereas	NULL
no	NULL
activity	NULL
of	NULL
this	NULL
promoter	NULL
was	NULL
detectable	NULL
in	NULL
nonhematopoietic	NULL
cells	NULL
.	NULL

This	NULL
promoter	NULL
activity	NULL
parallels	NULL
transcription	NULL
of	NULL
the	NULL
yc	NULL
gene	NULL
in	NULL
the	NULL
different	NULL
cell	NULL
lines	NULL
.	NULL

Tissue	NULL
specificity	NULL
of	NULL
the	NULL
promoter	NULL
activity	NULL
was	NULL
conserved	NULL
in	NULL
the	NULL
deletion	NULL
constructs	NULL
maintaining	NULL
90	NULL
bp	NULL
of	NULL
the	NULL
5	NULL
'	NULL
regulatory	NULL
region	NULL
.	NULL

No	NULL
negative	NULL
regulatory	NULL
region	NULL
clearly	NULL
appeared	NULL
in	NULL
our	NULL
study	NULL
as	NULL
previously	NULL
suggested	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Since	NULL
Jurkat	NULL
cells	NULL
were	NULL
tested	NULL
in	NULL
both	NULL
analyses	NULL
,	NULL
differences	NULL
between	NULL
the	NULL
deletion	NULL
mutant	NULL
constructs	NULL
analyzed	NULL
in	NULL
each	NULL
study	NULL
may	NULL
account	NULL
for	NULL
this	NULL
apparent	NULL
discrepancy	NULL
.	NULL

The	NULL
various	NULL
putative	NULL
cis-acting	NULL
elements	NULL
identified	NULL
upstream	NULL
of	NULL
the	NULL
-117-bp	NULL
fragment	NULL
do	NULL
not	NULL
appear	NULL
essential	NULL
for	NULL
promoter	NULL
activity	NULL
in	NULL
Raji	NULL
cells	NULL
since	NULL
similar	NULL
promoter	NULL
activity	NULL
was	NULL
observed	NULL
either	NULL
with	NULL
the	NULL
largest	NULL
construct	NULL
(	NULL
-1053	NULL
bp	NULL
)	NULL
or	NULL
with	NULL
shorter	NULL
constructs	NULL
containing	NULL
up	NULL
to	NULL
-117	NULL
bp	NULL
.	NULL

A	NULL
slight	NULL
progressive	NULL
decrease	NULL
in	NULL
promoter	NULL
activity	NULL
was	NULL
observed	NULL
in	NULL
other	NULL
hematopoietic	NULL
cells	NULL
.	NULL

These	NULL
elements	NULL
are	NULL
even	NULL
not	NULL
essential	NULL
for	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
gene	NULL
since	NULL
the	NULL
-90/+34	NULL
region	NULL
which	NULL
defines	NULL
the	NULL
basal	NULL
promoter	NULL
activity	NULL
allows	NULL
similar	NULL
cell	NULL
type-specific	NULL
expression	NULL
as	NULL
largest	NULL
constructs	NULL
.	NULL

This	NULL
tissue-specific	NULL
basal	NULL
promoter	NULL
activity	NULL
is	NULL
dependent	NULL
upon	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
first	NULL
EBS	NULL
(	NULL
-68	NULL
)	NULL
as	NULL
depicted	NULL
by	NULL
mutational	NULL
analysis	NULL
,	NULL
and	NULL
its	NULL
activity	NULL
is	NULL
not	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
14854	NULL
A	NULL
B	NULL
Regulation	NULL
of	NULL
ye	NULL
Gene	NULL
Promoter	NULL
Activity	NULL
by	NULL
Ets	NULL
Products	NULL
140000	NULL
7	NULL
140000	NULL
~	NULL
120000	NULL
7	NULL
120000	NULL
&	NULL
100000	NULL
{	NULL
100000	NULL
>	NULL
£	NULL
J	NULL
g	NULL
80000	NULL
7	NULL
80000	NULL
&	NULL
®	NULL
ka	NULL
£	NULL
©0000	NULL
-	NULL
60000	NULL
&	NULL
=	NULL
rl	NULL
40000	NULL
-	NULL
40000	NULL
4	NULL
20000	NULL
~	NULL
20000	NULL
4	NULL
o	NULL
44	NULL
o	NULL
=	NULL
G1bS	NULL
H4	NULL
Mut	NULL
G1bS	NULL
G1bS	NULL
G1bS	NULL
H4	NULL
Mut	NULL
20	NULL
ng	NULL
-	NULL
10nga	NULL
_	NULL
20ng	NULL
10	NULL
ng	NULL
«	NULL
50	NULL
ng	NULL
50	NULL
ng	NULL
50	NULL
ng	NULL
50	NULL
ng	NULL
50	NULL
ng	NULL
25	NULL
ng	NULL
a	NULL
-	NULL
50	NULL
ng	NULL
25	NULL
ng	NULL
«	NULL
AEB	NULL
+10	NULL
ng	NULL
B	NULL
-	NULL
AEB	NULL
-	NULL
+10	NULL
ng	NULL
$	NULL
B	NULL
AEB	NULL
-	NULL
E1	NULL
_	NULL
AEB	NULL
_	NULL
a	NULL
AEB	NULL
-	NULL
+25	NULL
ng	NULL
B-	NULL
AEB	NULL
-	NULL
+25	NULL
ng	NULL
B	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

Transactivation	NULL
assay	NULL
of	NULL
yc	NULL
basal	NULL
promoter	NULL
construct	NULL
using	NULL
GABP	NULL
or	NULL
Elf-1	NULL
expression	NULL
vectors	NULL
.	NULL

Helia	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
500	NULL
ng	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
(	NULL
GIbS	NULL
)	NULL
or	NULL
mutated	NULL
(	NULL
H4	NULL
)	NULL
-90/+34	NULL
construct	NULL
and	NULL
either	NULL
the	NULL
expression	NULL
plasmid	NULL
or	NULL
the	NULL
empty	NULL
expression	NULL
vector	NULL
AEB	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Different	NULL
amounts	NULL
of	NULL
expressions	NULL
vectors	NULL
were	NULL
used	NULL
in	NULL
A	NULL
and	NULL
B.	NULL
GABPa	NULL
and	NULL
GABPB	NULL
are	NULL
indicated	NULL
as	NULL
«	NULL
and	NULL
B	NULL
on	NULL
the	NULL
graph	NULL
.	NULL

Cotransfection	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
,	NULL
and	NULL
the	NULL
results	NULL
presented	NULL
here	NULL
are	NULL
means	NULL
of	NULL
several	NULL
assays	NULL
.	NULL

affected	NULL
by	NULL
mutation	NULL
in	NULL
the	NULL
second	NULL
putative	NULL
EBS	NULL
(	NULL
-53	NULL
)	NULL
.	NULL

Ets	NULL
factors	NULL
represent	NULL
a	NULL
group	NULL
of	NULL
proteins	NULL
containing	NULL
an	NULL
85-amino	NULL
acid	NULL
Ets	NULL
domain	NULL
that	NULL
interacts	NULL
with	NULL
a	NULL
purine-rich	NULL
core	NULL
sequence	NULL
,	NULL
GGA	NULL
(	NULL
A/T	NULL
)	NULL
.	NULL

Many	NULL
members	NULL
of	NULL
this	NULL
family	NULL
(	NULL
e.g	NULL
.	NULL

Spi-1	NULL
,	NULL
Spi-B	NULL
,	NULL
Ets-1	NULL
,	NULL
Ets-2	NULL
,	NULL
Elf-1	NULL
,	NULL
Fli-1	NULL
,	NULL
Erg	NULL
,	NULL
and	NULL
GABP	NULL
)	NULL
are	NULL
expressed	NULL
in	NULL
hematopoietic	NULL
cells	NULL
(	NULL
16	NULL
,	NULL
35	NULL
,	NULL
37	NULL
)	NULL
and	NULL
several	NULL
of	NULL
them	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
function	NULL
as	NULL
transcriptional	NULL
activa-tors	NULL
,	NULL
further	NULL
supporting	NULL
a	NULL
role	NULL
for	NULL
Ets	NULL
protein	NULL
in	NULL
lineage	NULL
commitment	NULL
and	NULL
stage	NULL
progression	NULL
during	NULL
hematopoiesis	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
Raji	NULL
or	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
,	NULL
the	NULL
-68	NULL
EBS	NULL
of	NULL
the	NULL
yc	NULL
promoter	NULL
binds	NULL
in	NULL
vitro	NULL
GABP	NULL
heteromeric	NULL
complexes	NULL
and	NULL
EIf-1	NULL
.	NULL

Among	NULL
these	NULL
two	NULL
factors	NULL
,	NULL
only	NULL
GABPa	NULL
when	NULL
cotransfected	NULL
in	NULL
Hela	NULL
cells	NULL
with	NULL
GABPB	NULL
was	NULL
able	NULL
by	NULL
binding	NULL
the	NULL
-68	NULL
EBS	NULL
to	NULL
induce	NULL
some	NULL
degree	NULL
of	NULL
transactivation	NULL
of	NULL
the	NULL
ye	NULL
promoter	NULL
indicating	NULL
that	NULL
GABP	NULL
«	NULL
-GABPB	NULL
complex	NULL
is	NULL
a	NULL
transcriptional	NULL
activator	NULL
in	NULL
this	NULL
context	NULL
.	NULL

Since	NULL
GABP	NULL
is	NULL
expressed	NULL
in	NULL
both	NULL
hematopoietic	NULL
cells	NULL
,	NULL
particularly	NULL
in	NULL
the	NULL
thymus	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
and	NULL
nonhematopoietic	NULL
cells	NULL
,	NULL
it	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
yc	NULL
promoter	NULL
activity	NULL
.	NULL

However	NULL
,	NULL
it	NULL
seems	NULL
unlikely	NULL
,	NULL
because	NULL
of	NULL
its	NULL
wide	NULL
tissue	NULL
expression	NULL
(	NULL
38	NULL
)	NULL
,	NULL
that	NULL
GABP	NULL
alone	NULL
could	NULL
account	NULL
for	NULL
the	NULL
tissue-specific	NULL
activity	NULL
exhibited	NULL
by	NULL
the	NULL
-90/+34	NULL
promoter	NULL
construct	NULL
.	NULL

Cell-type	NULL
specificity	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
conferred	NULL
either	NULL
by	NULL
specific	NULL
post-trans-lational	NULL
modifications	NULL
of	NULL
GABP	NULL
and/or	NULL
by	NULL
interactions	NULL
with	NULL
tissue-specific	NULL
cofactors	NULL
.	NULL

Interestingly	NULL
,	NULL
an	NULL
essential	NULL
EBS	NULL
was	NULL
also	NULL
identified	NULL
in	NULL
the	NULL
enhancer	NULL
region	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
start	NULL
of	NULL
transcription	NULL
of	NULL
the	NULL
chain	NULL
gene	NULL
(	NULL
39	NULL
)	NULL
with	NULL
binding	NULL
activity	NULL
for	NULL
GABP	NULL
and	NULL
Ets-1	NULL
.	NULL

yc	NULL
promoter	NULL
also	NULL
shares	NULL
with	NULL
the	NULL
promoter	NULL
housekeeping	NULL
promoter	NULL
characteristics	NULL
including	NULL
lack	NULL
of	NULL
TATA	NULL
,	NULL
CAAT	NULL
boxes	NULL
,	NULL
and	NULL
initiator	NULL
elements	NULL
,	NULL
whereas	NULL
an	NULL
Ets	NULL
DNA	NULL
binding	NULL
motif	NULL
was	NULL
found	NULL
close	NULL
to	NULL
the	NULL
transcriptional	NULL
initiation	NULL
site	NULL
.	NULL

It	NULL
was	NULL
previously	NULL
suggested	NULL
that	NULL
Ets	NULL
proteins	NULL
bound	NULL
to	NULL
the	NULL
latter	NULL
EBS	NULL
of	NULL
such	NULL
promoter	NULL
organization	NULL
could	NULL
recruit	NULL
other	NULL
transcriptional	NULL
factors	NULL
to	NULL
form	NULL
a	NULL
transcriptional	NULL
initiation	NULL
complex	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Housekeeping	NULL
gene	NULL
promoter	NULL
structure	NULL
associated	NULL
as	NULL
in	NULL
the	NULL
yc	NULL
promoter	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
multiple	NULL
putative	NULL
or	NULL
proven	NULL
Ets	NULL
binding	NULL
sequences	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
was	NULL
also	NULL
identified	NULL
in	NULL
promoters	NULL
that	NULL
direct	NULL
tissue-	NULL
or	NULL
stage-specific	NULL
gene	NULL
expression	NULL
.	NULL

As	NULL
postulated	NULL
by	NULL
Bittinger	NULL
et	NULL
al	NULL
.	NULL

(	NULL
40	NULL
)	NULL
,	NULL
recruitment	NULL
and	NULL
regulated	NULL
expression	NULL
of	NULL
the	NULL
general	NULL
transcription	NULL
machinery	NULL
in	NULL
this	NULL
setting	NULL
may	NULL
take	NULL
place	NULL
by	NULL
providing	NULL
a	NULL
joint	NULL
activation	NULL
domain	NULL
formed	NULL
by	NULL
the	NULL
concerted	NULL
binding	NULL
of	NULL
the	NULL
Ets	NULL
factors	NULL
or	NULL
association	NULL
with	NULL
another	NULL
activator	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
.	NULL

Elf-1	NULL
as	NULL
well	NULL
as	NULL
non-identified	NULL
Ets-related	NULL
members	NULL
other	NULL
than	NULL
Spi-1	NULL
,	NULL
Ets-1	NULL
,	NULL
or	NULL
Fli-1	NULL
also	NULL
bind	NULL
to	NULL
the	NULL
EBS	NULL
of	NULL
the	NULL
yc	NULL
gene	NULL
promoter	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
GABP	NULL
which	NULL
appears	NULL
to	NULL
be	NULL
widely	NULL
expressed	NULL
,	NULL
Elf-1	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
more	NULL
specific	NULL
to	NULL
lymphoid	NULL
tissues	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Since	NULL
we	NULL
failed	NULL
to	NULL
detect	NULL
activation	NULL
of	NULL
the	NULL
-90/+34	NULL
promoter	NULL
construct	NULL
with	NULL
EIf-1	NULL
,	NULL
interaction	NULL
with	NULL
other	NULL
(	NULL
s	NULL
)	NULL
proteins	NULL
binding	NULL
further	NULL
upstream	NULL
in	NULL
the	NULL
yc	NULL
promoter	NULL
region	NULL
may	NULL
be	NULL
important	NULL
for	NULL
its	NULL
specific	NULL
regulation	NULL
.	NULL

ye	NULL
gene	NULL
defect	NULL
causes	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
whose	NULL
curative	NULL
therapy	NULL
until	NULL
now	NULL
depends	NULL
on	NULL
bone	NULL
marrow	NULL
transplantation	NULL
success	NULL
.	NULL

The	NULL
severity	NULL
of	NULL
this	NULL
disease	NULL
and	NULL
the	NULL
recent	NULL
cloning	NULL
of	NULL
the	NULL
yc	NULL
chain	NULL
gene	NULL
enable	NULL
us	NULL
to	NULL
consider	NULL
gene	NULL
therapy	NULL
as	NULL
a	NULL
potential	NULL
therapeutic	NULL
option	NULL
especially	NULL
in	NULL
patients	NULL
with	NULL
no	NULL
HLA-compatible	NULL
donor	NULL
.	NULL

Retroviral	NULL
yc	NULL
gene	NULL
construct	NULL
controlled	NULL
by	NULL
long	NULL
terminal	NULL
repeat-based	NULL
promoter	NULL
could	NULL
permit	NULL
yc	NULL
gene	NULL
transfer	NULL
into	NULL
SCID	NULL
X1	NULL
hematopoietic	NULL
CD34	NULL
*	NULL
stem	NULL
cells	NULL
with	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
in	NULL
the	NULL
various	NULL
hematopoietic	NULL
lineages	NULL
.	NULL
``	NULL

However	NULL
,	NULL
overexpression	NULL
of	NULL
yc	NULL
gene	NULL
at	NULL
discrete	NULL
stages	NULL
of	NULL
lymphoid	NULL
(	NULL
12	NULL
)	NULL
or	NULL
myeloid	NULL
development	NULL
or	NULL
inadequate	NULL
ye	NULL
gene	NULL
expression	NULL
at	NULL
the	NULL
surface	NULL
of	NULL
red	NULL
blood	NULL
cells	NULL
or	NULL
platelets	NULL
may	NULL
be	NULL
deleterious	NULL
.	NULL

If	NULL
such	NULL
fine	NULL
yc	NULL
transcription	NULL
regulation	NULL
is	NULL
needed	NULL
,	NULL
a	NULL
more	NULL
physiologic	NULL
control	NULL
of	NULL
yc	NULL
gene	NULL
expression	NULL
will	NULL
be	NULL
required	NULL
.	NULL

The	NULL
data	NULL
herein	NULL
reported	NULL
delineating	NULL
a	NULL
tissue-specific	NULL
promoter	NULL
activity	NULL
in	NULL
less	NULL
than	NULL
1-kilobase	NULL
pair	NULL
make	NULL
feasible	NULL
the	NULL
construction	NULL
of	NULL
ye	NULL
gene	NULL
expression	NULL
vectors	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
minimal	NULL
tissue-specific	NULL
promoter	NULL
determining	NULL
appropriate	NULL
basal	NULL
yc	NULL
gene	NULL
expression	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
R.	NULL
de	NULL
Chasseval	NULL
for	NULL
help	NULL
in	NULL
determination	NULL
of	NULL
transfection	NULL
assay	NULL
conditions	NULL
and	NULL
to	NULL
Drs	NULL
.	NULL

A.	NULL
Gégonne	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

*	NULL
G.	NULL
de	NULL
Saint	NULL
Basile	NULL
,	NULL
unpublished	NULL
data	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Regulation	NULL
of	NULL
ye	NULL
Gene	NULL
Promoter	NULL
Activity	NULL
by	NULL
Ets	NULL
Products	NULL
Brown	NULL
,	NULL
J.	NULL
M.	NULL
Leiden	NULL
,	NULL
S.	NULL
L.	NULL
Mc	NULL
Knight	NULL
,	NULL
and	NULL
K.	NULL
Sugamura	NULL
for	NULL
providing	NULL
reagents	NULL
.	NULL

We	NULL
sincerely	NULL
thank	NULL
Béatrice	NULL
Neveu	NULL
for	NULL
typing	NULL
the	NULL
manuscript	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

REFERENCES	NULL
.	NULL

Takeshita	NULL
,	NULL
T.	NULL
,	NULL
Asao	NULL
,	NULL
H.	NULL
,	NULL
Ohtani	NULL
,	NULL
K.	NULL
,	NULL
Ishii	NULL
,	NULL
N.	NULL
,	NULL
Kumaki	NULL
,	NULL
S.	NULL
,	NULL
Tanaka	NULL
,	NULL
N.	NULL
,	NULL
Mu	NULL
nakata	NULL
,	NULL
H.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
379-382	NULL
.	NULL

Kondo	NULL
,	NULL
M.	NULL
,	NULL
Takeshita	NULL
,	NULL
T.	NULL
,	NULL
Ishii	NULL
,	NULL
N.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
Watanabe	NULL
,	NULL
S.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
and	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
1874-1877	NULL
.	NULL

Russell	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Keegan	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Harada	NULL
,	NULL
N.	NULL
,	NULL
Nakamura	NULL
,	NULL
Y.	NULL
,	NULL
Noguchi	NULL
,	NULL
M.	NULL
,	NULL
Leland	NULL
,	NULL
P.	NULL
,	NULL
Friedmann	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Miyajima	NULL
,	NULL
A.	NULL
,	NULL
Puri	NULL
,	NULL
R.	NULL
K.	NULL
,	NULL
Paul	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
and	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
1880-1883	NULL
.	NULL

Noguchi	NULL
,	NULL
M.	NULL
,	NULL
Nakamura	NULL
,	NULL
Y.	NULL
,	NULL
Russell	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Ziegler	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
Tsang	NULL
,	NULL
M.	NULL
,	NULL
Cao	NULL
,	NULL
X.	NULL
,	NULL
and	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
1877-1880	NULL
.	NULL

Kondo	NULL
,	NULL
M.	NULL
,	NULL
Takeshita	NULL
,	NULL
T.	NULL
,	NULL
Higuchi	NULL
,	NULL
M.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
Sudo	NULL
,	NULL
T.	NULL
,	NULL
Nishikawa	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Science	NULL
268	NULL
,	NULL
1453-1454	NULL
.	NULL

Kimura	NULL
,	NULL
Y.	NULL
,	NULL
Takeshita	NULL
,	NULL
T.	NULL
,	NULL
Kondo	NULL
,	NULL
M.	NULL
,	NULL
Ishii	NULL
,	NULL
N.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
Van	NULL
Snick	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
115-120	NULL
.	NULL

Giri	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Abdieh	NULL
,	NULL
M.	NULL
,	NULL
Eisenman	NULL
,	NULL
J.	NULL
,	NULL
Shanebeck	NULL
,	NULL
K.	NULL
,	NULL
Grabstein	NULL
,	NULL
K.	NULL
,	NULL
Kumaki	NULL
,	NULL
S.	NULL
,	NULL
Namen	NULL
,	NULL
A.	NULL
,	NULL
Park	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
Cosman	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Anderson	NULL
,	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

13	NULL
,	NULL
2822-2830	NULL
.	NULL

Noguchi	NULL
,	NULL
M.	NULL
,	NULL
Yi	NULL
,	NULL
H.	NULL
,	NULL
Rosenblatt	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Filipovich	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
Adelstein	NULL
,	NULL
S.	NULL
,	NULL
Modi	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Mc	NULL
Bride	NULL
,	NULL
O.	NULL
W.	NULL
,	NULL
and	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
78	NULL
,	NULL
147-157	NULL
.	NULL

Ammann	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Hong	NULL
,	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
in	NULL
Immunological	NULL
Disorders	NULL
in	NULL
Infants	NULL
and	NULL
Children	NULL
(	NULL
Stiehm	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
ed	NULL
)	NULL
pp	NULL
.	NULL

257-315	NULL
,	NULL
W.	NULL
B.	NULL
Saunders	NULL
Co.	NULL
,	NULL
Phila-delphia	NULL
,	NULL
PA	NULL
Ishii	NULL
,	NULL
N.	NULL
,	NULL
Takeshita	NULL
,	NULL
T.	NULL
,	NULL
Kimura	NULL
,	NULL
Y.	NULL
,	NULL
Tada	NULL
,	NULL
K.	NULL
,	NULL
Kondo	NULL
,	NULL
M.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

6	NULL
,	NULL
1278-1277	NULL
DiSanto	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Certain	NULL
,	NULL
S.	NULL
,	NULL
Wilson	NULL
,	NULL
A.	NULL
,	NULL
MacDonald	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
Avner	NULL
,	NULL
P.	NULL
,	NULL
Fischer	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
de	NULL
Saint	NULL
Basile	NULL
,	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24	NULL
,	NULL
3014-3018	NULL
Kondo	NULL
,	NULL
M.	NULL
,	NULL
Ohashi	NULL
,	NULL
Y.	NULL
,	NULL
Tada	NULL
,	NULL
K.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24	NULL
,	NULL
2026-2030	NULL
Ohbo	NULL
,	NULL
K.	NULL
,	NULL
Takasawa	NULL
,	NULL
N.	NULL
,	NULL
Ishii	NULL
,	NULL
N.	NULL
,	NULL
Tanaka	NULL
,	NULL
N.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
7479-7486	NULL
Bosco	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Espinoza-Delgado	NULL
,	NULL
I.	NULL
,	NULL
Schwabe	NULL
,	NULL
M.	NULL
,	NULL
Gusella	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L..	NULL
,	NULL
Sugamura	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Varesio	NULL
,	NULL
L.	NULL
(	NULL
1994	NULL
)	NULL
Blood	NULL
88	NULL
,	NULL
2995-3002	NULL
Bhat	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
and	NULL
Papas	NULL
,	NULL
T.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
in	NULL
Challenges	NULL
of	NULL
Modern	NULL
Medicine	NULL
(	NULL
Verna	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Shamoo	NULL
,	NULL
A.	NULL
,	NULL
eds	NULL
)	NULL
pp	NULL
.	NULL

63-83	NULL
,	NULL
Ares-Serono	NULL
Symposia	NULL
Publications	NULL
,	NULL
Rome	NULL
,	NULL
Italy	NULL
Romano-Spica	NULL
,	NULL
V.	NULL
,	NULL
Suzuki	NULL
,	NULL
H.	NULL
,	NULL
Georgiou	NULL
,	NULL
P.	NULL
,	NULL
Chen	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Ascione	NULL
,	NULL
R.	NULL
,	NULL
Papas	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
and	NULL
Bhat	NULL
,	NULL
N.	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Int	NULL
.	NULL

J.	NULL
Oncol	NULL
.	NULL

4	NULL
,	NULL
521-581	NULL
Duprez	NULL
,	NULL
V.	NULL
,	NULL
Lenoir	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Dautry-Varsat	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

82	NULL
,	NULL
6932-6936	NULL
Duprez	NULL
,	NULL
V.	NULL
,	NULL
Cornet	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Dautry-Varsat	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
12860-12865	NULL
Teshigawara	NULL
,	NULL
K.	NULL
,	NULL
Wang	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Kato	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165	NULL
,	NULL
223-238	NULL
20	NULL
21	NULL
22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

14855	NULL
.	NULL

Nizetic	NULL
,	NULL
J.	NULL
,	NULL
Zehetener	NULL
,	NULL
G.	NULL
,	NULL
Monaco	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
Gellen	NULL
,	NULL
L.	NULL
,	NULL
Young	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
and	NULL
Lehrach	NULL
,	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
3233-3237	NULL
.	NULL

Noguchi	NULL
,	NULL
M.	NULL
,	NULL
Adelstein	NULL
,	NULL
S.	NULL
,	NULL
Cao	NULL
,	NULL
X.	NULL
,	NULL
and	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
13601-13608	NULL
Nordeen	NULL
,	NULL
S.	NULL
K.	NULL
(	NULL
1988	NULL
)	NULL
BioTechniques	NULL
6	NULL
,	NULL
454-457	NULL
Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Merlino	NULL
,	NULL
G.	NULL
T.	NULL
,	NULL
Willingham	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Pastan	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Howard	NULL
,	NULL
B.	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

79	NULL
,	NULL
6777-6781	NULL
Boulukos	NULL
,	NULL
K.	NULL
,	NULL
Pognonec	NULL
,	NULL
P.	NULL
,	NULL
Rabault	NULL
,	NULL
B.	NULL
,	NULL
Begue	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Ghysdael	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9	NULL
,	NULL
5718-5721	NULL
Potter	NULL
,	NULL
H.	NULL
,	NULL
Weir	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Leder	NULL
,	NULL
P.	NULL
(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

81	NULL
,	NULL
7161-7165	NULL
Graham	NULL
,	NULL
F.	NULL
L.	NULL
,	NULL
and	NULL
Van	NULL
der	NULL
Eb	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1973	NULL
)	NULL
Virology	NULL
52	NULL
,	NULL
456-467	NULL
Han	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Stratowa	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Rutter	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Biochemistry	NULL
26	NULL
,	NULL
1617-1625	NULL
Ishii	NULL
,	NULL
N.	NULL
,	NULL
Asao	NULL
,	NULL
H.	NULL
,	NULL
Kimura	NULL
,	NULL
Y.	NULL
,	NULL
Takeshita	NULL
,	NULL
T.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
Tsuchiya	NULL
S.	NULL
,	NULL
Konno	NULL
,	NULL
T.	NULL
,	NULL
Maeda	NULL
,	NULL
M.	NULL
,	NULL
Uchiyama	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

153	NULL
,	NULL
1310-1317	NULL
Gougeon	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Drean	NULL
,	NULL
G.	NULL
,	NULL
Le	NULL
Deist	NULL
,	NULL
F.	NULL
,	NULL
Doussau	NULL
,	NULL
M.	NULL
,	NULL
Fevrier	NULL
,	NULL
M.	NULL
,	NULL
Diu	NULL
,	NULL
A.	NULL
,	NULL
Theze	NULL
,	NULL
J.	NULL
,	NULL
Griscelli	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Fischer	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

145	NULL
,	NULL
2873-2879	NULL
Bosselut	NULL
,	NULL
R.	NULL
,	NULL
Duvall	NULL
,	NULL
J.	NULL
,	NULL
Gégonne	NULL
,	NULL
A.	NULL
,	NULL
Bailly	NULL
,	NULL
M.	NULL
,	NULL
Hemar	NULL
,	NULL
A.	NULL
,	NULL
Brady	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Ghysdael	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
3137-3144	NULL
Goldberg	NULL
,	NULL
Y.	NULL
,	NULL
Glineur	NULL
,	NULL
C.	NULL
,	NULL
Gesquiere	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Ricouart	NULL
,	NULL
A.	NULL
,	NULL
Sap	NULL
,	NULL
J.	NULL
,	NULL
Vennstrim	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Ghysdael	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

7	NULL
,	NULL
2425-2433	NULL
Ghysdael	NULL
,	NULL
J.	NULL
,	NULL
Gégonne	NULL
,	NULL
A.	NULL
,	NULL
Pognonesc	NULL
,	NULL
P.	NULL
,	NULL
Dernis	NULL
,	NULL
D.	NULL
,	NULL
Leprince	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Stehelin	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
1714-1718	NULL
Bailly	NULL
,	NULL
R.-A	NULL
.	NULL

,	NULL
Bosselut	NULL
,	NULL
R.	NULL
,	NULL
Zucman	NULL
,	NULL
J.	NULL
,	NULL
Cormier	NULL
,	NULL
F.	NULL
,	NULL
Delattre	NULL
,	NULL
O.	NULL
,	NULL
Roussel	NULL
,	NULL
M.	NULL
,	NULL
Thomas	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Ghysdael	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
3230-3241	NULL
Bosselut	NULL
,	NULL
R.	NULL
,	NULL
Levin	NULL
,	NULL
J.	NULL
,	NULL
Adjadj	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Ghysdael	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

21	NULL
,	NULL
5184-5191	NULL
Nye	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Petersen	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Gunther	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
Jonsen	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
and	NULL
Graves	NULL
,	NULL
B.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

6	NULL
,	NULL
975-990	NULL
Thompson	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Brown	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Mc	NULL
Knight	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
258	NULL
,	NULL
762-768	NULL
Macleod	NULL
,	NULL
K.	NULL
,	NULL
Leprince	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Stehelin	NULL
,	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

17	NULL
,	NULL
251-256	NULL
LaMarco	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
Thompson	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Byers	NULL
,	NULL
B.	NULL
P.	NULL
,	NULL
Walton	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
and	NULL
Mc	NULL
Knight	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
258	NULL
,	NULL
789-792	NULL
Lin	NULL
,	NULL
J.	NULL
X.	NULL
,	NULL
Bhat	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
John	NULL
,	NULL
S.	NULL
,	NULL
Queale	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
and	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
6201-6210	NULL
Bittinger	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Shelley	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Farokhzad	NULL
,	NULL
O.	NULL
C.	NULL
,	NULL
and	NULL
Arnaout	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
2604-2615	NULL
Virbasius	NULL
,	NULL
J.	NULL
V.	NULL
,	NULL
Virbasius	NULL
,	NULL
C.-M.	NULL
,	NULL
and	NULL
Scarpulla	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1993	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
380-392	NULL
Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Wang	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Ho	NULL
,	NULL
I.	NULL
C.	NULL
,	NULL
Bohjanen	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Petryniak	NULL
,	NULL
B.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Miesfeldt	NULL
,	NULL
S.	NULL
,	NULL
Zhang	NULL
,	NULL
L.	NULL
,	NULL
Nabel	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Karpinski	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
1048-1053	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Tissue-specific	NULL
Activity	NULL
of	NULL
the	NULL
yc	NULL
Chain	NULL
Gene	NULL
Promoter	NULL
Depends	NULL
upon	NULL
an	NULL
Ets	NULL
Binding	NULL
Site	NULL
and	NULL
Is	NULL
Regulated	NULL
by	NULL
GA	NULL
-binding	NULL
Protein	NULL
Sophie	NULL
Markiewicz	NULL
,	NULL
Rémy	NULL
Bosselut	NULL
,	NULL
Frangoise	NULL
Le	NULL
Deist	NULL
,	NULL
Jean-Pierre	NULL
de	NULL
Villartay	NULL
,	NULL
Claire	NULL
Hivroz	NULL
,	NULL
Jacques	NULL
Ghysdael	NULL
,	NULL
Alain	NULL
Fischer	NULL
and	NULL
Genevieve	NULL
de	NULL
Saint	NULL
Basile	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1996	NULL
,	NULL
271:14849-14855.	NULL
doi	NULL
:	NULL
10.1074/jb0.271.25.14849	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/271/25/1	NULL
4849	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
40	NULL
references	NULL
,	NULL
26	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
4849.	NULL
full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
4q	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL

